

# **cobas<sup>®</sup> TV/MG**

---

## **Qualitative nucleic acid test for use on the cobas<sup>®</sup> 5800/6800/8800 systems**

For in vitro diagnostic use

**cobas<sup>®</sup> TV/MG**

P/N: 09040633190

**For use on the cobas<sup>®</sup> 5800 system**

**cobas<sup>®</sup> TV/MG Positive Control Kit**

P/N: 09040641190

**cobas<sup>®</sup> Buffer Negative Control Kit**

P/N: 09051953190

**For use on the cobas<sup>®</sup> 6800/8800 systems**

**cobas<sup>®</sup> TV/MG Positive Control Kit**

P/N: 07948689190 or

P/N: 09040641190

**cobas<sup>®</sup> Buffer Negative Control Kit**

P/N: 07002238190 or

P/N: 09051953190

# Table of contents

<b>Intended use .....</b>	<b>5</b>
<b>Summary and explanation of the test.....</b>	<b>5</b>
<b>Reagents and materials.....</b>	<b>8</b>
cobas® TV/MG reagents and controls .....	8
cobas® omni reagents for sample preparation.....	9
Reagent storage requirements .....	10
Reagent handling requirements for cobas® 5800 system or cobas® 6800/8800 systems .....	10
Additional materials required for cobas® 5800/6800/8800 systems .....	12
Instrumentation and software required .....	13
Additional materials required for sample collection for cobas® TV/MG .....	13
Additional materials required for sample aliquoting and sample loading for cobas® TV/MG .....	14
<b>Precautions and handling requirements .....</b>	<b>14</b>
Warnings and precautions .....	14
Reagent handling.....	15
Good laboratory practice.....	15
<b>Specimen collection, transport, and storage.....</b>	<b>16</b>
Specimen collection .....	16
Specimen transport .....	16
Specimen storage.....	16
Male and female urine specimens .....	16
Endocervical and vaginal specimens .....	17
Meatal specimens .....	18
Cervical specimens in PreservCyt® Solution.....	18
cobas® 5800 system .....	18
cobas® 5800/6800/8800 systems.....	19

<b>Instructions for use.....</b>	<b>19</b>
Procedural notes.....	19
Running cobas® TV/MG on cobas® 5800/6800/8800 systems.....	19
<b>Results.....</b>	<b>23</b>
Quality control and validity of results on cobas® 5800 system and cobas® 6800/8800 systems with software version 2.0 or higher .....	23
Quality control and validity of results on cobas® 6800/8800 systems with software version 1.4.....	23
Interpretation of results on the cobas® 5800 system and cobas® 6800/8800 systems with software version 2.0 or higher .....	24
Interpretation of results on the cobas® 6800/8800 systems with software version 1.4 .....	24
Interpretation of results for cobas® 5800/6800/8800 systems.....	26
Procedural limitations .....	28
<b>Non-clinical performance evaluation.....</b>	<b>29</b>
System equivalency .....	29
Key performance characteristics .....	29
Limit of Detection (LoD).....	29
Inclusivity.....	29
Precision.....	29
Analytical specificity/cross reactivity .....	31
Interference.....	33
Competitive inhibition.....	34
Whole system failure .....	34
Cross contamination .....	34
<b>Clinical performance evaluation .....</b>	<b>35</b>
<b>Additional information .....</b>	<b>40</b>
Key assay features.....	40
Symbols.....	41
Technical support.....	42
Manufacturer and importer .....	42

Trademarks and patents..... 42

Copyright..... 42

References..... 43

Document revision..... 45

## Intended use

**cobas®** TV/MG for use on the **cobas®** 5800/6800/8800 systems is an automated, qualitative in vitro diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the direct detection of *Trichomonas vaginalis* (TV) and/or *Mycoplasma genitalium* (MG) DNA in male and female urine, clinician-instructed self-collected vaginal swab specimens, clinician-collected vaginal swab specimens, endocervical swab specimens, clinician-instructed self-collected meatal swab specimens, clinician-collected meatal swab specimens, all collected in **cobas®** PCR Media (Roche Molecular Systems, Inc.), and cervical specimens collected in PreservCyt® Solution. This test is intended as an aid in the diagnosis of TV and MG caused disease in both symptomatic and asymptomatic individuals.

## Summary and explanation of the test

### Background

*Trichomonas vaginalis* is the most common non-viral sexually transmitted infection (STI) in the world, with an estimated 276.4 million cases in 2008 with an approximate prevalence in females and males of 8.1% and 1.0%, respectively.<sup>1</sup> However, these rates are thought to be an underestimation because most of the studies have been from methods such as wet mount microscopy versus nucleic acid amplification tests (NAATs). Global population based studies show rates ranging from 3.2% to 42.6%, depending on the geographic region studied.<sup>1</sup> *Trichomonas vaginalis* is also the most prevalent STI in the United States (US). A population-based study demonstrated an overall prevalence of 3.1% among women aged 14 to 49 years, with rates as high as 13.3% among black women in the general population.<sup>2</sup> Another study found TV prevalence of 11.9% in women aged 36 to 45, 7.7% in women aged 51 to 60, and 4.2% in women aged 16 to 25 years.<sup>3</sup> Molecular based tests for the detection of TV have shown a detection rate between 7% and 13% among females.<sup>4</sup> However, TV is currently not a reportable disease, and the true estimation of disease prevalence is not currently known. Some of the factors contributing to this are the lack of routine testing, low sensitivity (SENS) of the traditional laboratory tests, and non-specific symptomatology.

*Trichomonas vaginalis* is a parasitic protozoan that is approximately 10 to 20 µm in length and 2 to 14 µm in width, and it has four anterior flagella. *Trichomonas vaginalis* trophozoites divide by binary fission, and, in natural infections, give rise to a population in the lumen and on the mucosal surfaces of the urogenital tract of humans.<sup>5</sup> *Trichomonas vaginalis* primarily infects the squamous epithelial cells and erythrocytes and resides in the lower genital tract in females and in the male urethra and prostate in males.<sup>1</sup> Humans are the only known host for TV, and the pathogen is primarily sexually transmitted. Infection may persist for long periods (months to years) in women, but, in males, it generally persists less than ten days.

Women who are symptomatic for a TV infection complain of vaginal discharge, pruritus, and irritation. Other signs of infection include malodor, edema, and/or erythema. *Trichomonas vaginalis* is also known to cause urethritis in men who have sex with women. Men with trichomoniasis may feel itching or irritation inside the penis or burning after urination or ejaculation or have some discharge from the penis. Sviden et al observed a TV polymerase chain reaction (PCR) detection rate of 8.2% in 500 men with urethritis versus a 2.2% detection rate in asymptomatic males.<sup>4</sup>

Laboratory diagnosis has relied on viewing the organisms under the microscope via a saline wet mount prepared from the patient's discharge. The motile trichomonads can be observed; however, the wet mount microscopy must be analyzed within 10 to 20 minutes of sample collection as the organism will lose viability, and, therefore, the characteristic motility. Another caveat of wet mount microscopy is that white blood cells (WBCs) are often in the vaginal fluid collected, and WBCs can be mistaken for TV organisms. So, although wet mount microscopy is quick and inexpensive, there is limited

SENS, which ranges from 60% to 70%.<sup>5,6</sup>

The current gold standard for the laboratory diagnosis of TV is culture that can be performed in Diamond's medium. The commercially available, United States Food and Drug Administration (FDA)-approved InPouch™ TV (Biomed Diagnostics) is available for culture-based testing. Although the culture medium helps to maintain the viability of the TV organism, this testing remains relatively insensitive (73.3%).<sup>6</sup> Nucleic acid amplification testing has been shown to be more sensitive than the culture testing.<sup>7</sup>

The Centers for Disease Control and Prevention (CDC) recommends that women who test positive for TV be rescreened 3 months after treatment.<sup>8</sup> The CDC also recommends that women with human immunodeficiency virus (HIV) infection also be screened for TV at the initial visit and annually thereafter.

*Mycoplasma genitalium* is a fastidious bacterium first isolated in 1980 from the urethral swabs of two symptomatic men with non-gonococcal urethritis (NGU).<sup>9</sup> Infections caused by this bacterium have been associated with male and female urethritis, balanoposthitis, prostatitis, cervicitis, pelvic inflammatory disease, and male and female infertility.<sup>10</sup> Additional complications, such as preterm delivery and extra-genital infections, have been reported.

There have been few studies showing an accurate prevalence of MG because, historically, this bacterium is difficult to culture. However, a number of molecular assays have been described that show a prevalence as high as 47.5%.<sup>11</sup> Some of the factors accounting for the wide range in prevalence are related to the sample type (vaginal swab, urine, rectal swabs, or endocervical swabs) collected and the subjects selected. A recent study performed in 2016 from various public health clinics, family planning clinics, and hospital systems across the US using molecular methods showed the rates of prevalence at 16.3% and 17.2% for females and males, respectively.<sup>12</sup> Another study performed at a STI clinic showed that 17.5% of women tested positive for MG and that vaginal swabs have the highest relative SENS (85.7%), with urine samples showing a 61.4% relative SENS.<sup>13</sup> Mezzini et al showed that 8.1% (96/1,182) males who presented to a public sexual health clinic with symptoms of dysuria and/or urethral discharge had MG deoxyribonucleic acid (DNA) detected in their urine.<sup>14</sup>

Currently, there is no evidence-based consensus or gold-standard test for MG or a consensus sample type(s) to be collected. There are also no recommended guidelines for MG screening or testing, and the lack of a universally accepted, standardized assay complicates screening efforts for at-risk patient populations. Similar to TV, MG is not a reportable disease, and it is likely that, without laboratory testing available, some cases of MG infection are treated empirically as a *Chlamydia trachomatis* (CT) infection. There are also no recommended guidelines for retesting patients who have completed treatment for MG, although follow-up testing and reassessment may be indicated, depending on the patient's risk factors for re-infection and the history of and compliance with antibiotic treatment. Contributing to the potential need for retesting is the increased incidence of macrolide resistance when first line treatment may not work or work sub-optimally.<sup>12</sup>

## Explanation of the test

**cobas®** TV/MG for use on the **cobas®** 5800 system, **cobas®** 6800 system or **cobas®** 8800 system (referred to as **cobas®** TV/MG throughout the remainder of this document) is an automated, qualitative real-time PCR test designed to detect TV and MG DNA in urogenital specimens from male and female patients and thus fulfills the medical need for a rapid, high throughput molecular screening test for use as an aid in the diagnosis of TV and MG caused disease in both symptomatic and asymptomatic individuals. **cobas®** TV/MG enables the detection of TV and/or MG DNA in endocervical, vaginal, urine and cervical specimens of female patients and meatal and urine specimens of male patients. The DNA Internal Control, used to monitor the entire sample preparation and PCR amplification process, is introduced into each specimen during sample processing. In addition, the test utilizes a low titer positive and a negative control.

## Principles of the procedure

**cobas®** TV/MG is based on fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection. The **cobas®** 5800 system is designed as one integrated instrument. The **cobas®** 6800/8800 systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the **cobas®** 5800 system or **cobas®** 6800/8800 systems software which assigns test results for all tests as positive, negative or invalid. Results can be reviewed directly on the system screen, exported, or printed as a report.

Nucleic acid from patient samples, external controls and added internal control DNA (DNA-IC) molecules is simultaneously extracted. In summary, bacterial nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris and potential PCR inhibitors are removed with subsequent wash steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature.

Selective amplification of target nucleic acid from the sample is achieved by the use of target-specific forward and reverse primers for TV and MG which are selected from highly-conserved regions within the respective target organism. TV is detected by one selective set of primers and a probe, while MG uses two sets targeting separated regions (dual-target). Selective amplification of DNA IC is achieved by the use of sequence-specific forward and reverse primers which are selected to have no homology with either the TV or MG target regions. A thermostable DNA polymerase enzyme is used for PCR amplification. The target and DNA-IC sequences are amplified simultaneously utilizing a universal PCR amplification profile with predefined temperature steps and number of cycles. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythymidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon). Any contaminating amplicon from previous PCR runs are eliminated by the AmpErase enzyme, which is included in the PCR master mix, during the first thermal cycling step.<sup>15</sup> However, newly formed amplicon are not eliminated since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.

The **cobas®** TV/MG master mix contains one detection probe specific for the TV target sequence, two detection probes specific for the MG target sequences and one for the DNA-IC. The probes are labeled with target specific fluorescent reporter dyes allowing simultaneous detection of TV target, MG targets and DNA-IC in three different target channels.<sup>16,17</sup> When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by a quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage of the probe by the 5' to 3' exonuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye increases concomitantly. Real-time detection and discrimination of PCR products is accomplished by measuring the fluorescence of the released reporter dyes for the TV and MG targets and DNA-IC, respectively.

# Reagents and materials

## cobas® TV/MG reagents and controls

The materials provided for cobas® TV/MG can be found in Table 1. Materials required, but not provided can be found in Table 2, Table 3, Table 4, Table 10 and Table 11.

All unopened reagents and controls shall be stored as recommended in Table 1 to Table 4.

**Table 1 cobas® TV/MG**

**(cobas® TV/MG)**

Store at 2–8°C

384 test cassette (P/N 09040633190)

Kit components	Reagent ingredients	Quantity per kit 384 tests
<b>Proteinase Solution (PASE)</b>	Tris buffer, < 0.05% EDTA, Calcium chloride, Calcium acetate, 8% Proteinase EUH210: Safety data sheet available on request. EUH208: Contains subtilisin from <i>Bacillus subtilis</i> . May produce an allergic reaction.	38 mL
<b>DNA Internal Control (DNA-IC)</b>	Tris buffer, < 0.05% EDTA, < 0.001% non-TV/MG related DNA construct containing primer and probe specific sequence regions, < 0.1% Sodium azide	38 mL
<b>Elution Buffer (EB)</b>	Tris buffer, 0.2% Methyl-4 hydroxybenzoate	38 mL
<b>Master Mix Reagent 1 (MMX-R1)</b>	Manganese acetate, Potassium hydroxide, < 0.1% Sodium azide	14.5 mL
<b>TV/MG Master Mix Reagent 2 (TV/MG MMX-R2)</b>	Tricine buffer, Potassium acetate, EDTA, Glycerol, < 18% Dimethyl sulfoxide, < 0.12% dATP, dCTP, dGTP, dUTPs, < 0.1% Tween 20, < 0.1% Sodium azide, < 0.1% Z05 DNA polymerase, < 0.1% AmpErase (uracil-N glycosylase) enzyme (microbial), < 0.01% Internal Control forward and reverse primers, < 0.01% Upstream and downstream TV/MG primers, < 0.01% Fluorescent-labeled oligonucleotide probes specific for TV, MG and the DNA Internal Control, < 0.01% Oligonucleotide aptamer	17.5 mL

**Table 2 cobas® TV/MG Positive Control Kit**

**(cobas® TV/MG Positive Control Kit)**

Store at 2–8°C

For use on the cobas® 5800 system, and the cobas® 6800/8800 systems with software version 2.0 or higher (P/N 09040641190)

For use on the cobas® 6800/8800 systems with software version 1.4 (P/N 07948689190 and P/N 09040641190)

Kit components	Reagent ingredients	Quantity per kit
<b>TV/MG Positive Control (TV/MG (+) C)</b>	Tris buffer, < 0.05% Sodium azide, < 0.005% EDTA, < 0.003% Poly rA, < 0.01% Non-infectious plasmid DNA (microbial) containing <i>T. vaginalis</i> , < 0.01% Non-infectious plasmid DNA (microbial) containing <i>M. genitalium</i>	16 mL (16 x 1 mL)

**Table 3 cobas® Buffer Negative Control Kit**

**(cobas® Buffer Negative Control Kit)**

Store at 2–8°C

For use on the cobas® 5800 system, and the cobas® 6800/8800 systems with software version 2.0 or higher (P/N 09051953190)


For use on the cobas® 6800/8800 systems with software version 1.4 (P/N 07002238190 and P/N 09051953190)

Kit components	Reagent ingredients	Quantity per kit
<b>cobas® Buffer Negative Control (BUF (-) C)</b>	Tris buffer, < 0.1% sodium azide, EDTA, < 0.002% Poly rA RNA (synthetic)	16 mL (16 x 1 mL)



## cobas® omni reagents for sample preparation

**Table 4** cobas® omni reagents for sample preparation

Reagents	Reagent ingredients	Quantity per kit	Safety symbol and warning*
<b>cobas® omni MGP Reagent (MGP)</b> Store at 2–8°C (P/N 06997546190)	Magnetic glass particles, Tris buffer, 0.1% methyl-4 hydroxybenzoate, < 0.1% sodium azide	480 tests	Not applicable
<b>cobas® omni Specimen Diluent (SPEC DIL)</b> Store at 2–8°C (P/N 06997511190)	Tris buffer, 0.1% methyl-4 hydroxybenzoate, < 0.1% sodium azide	4 x 875 mL	Not applicable
<b>cobas® omni Lysis Reagent (LYS)</b> Store at 2–8°C (P/N 06997538190)	43% (w/w) guanidine thiocyanate**, 5% (w/v) polydocanol**, 2% (w/v) dithiothreitol**, dihydro sodium citrate EUH032: Contact with acids liberates very toxic gas.	4 x 875 mL	 <p><b>DANGER</b></p> <p>H302 + H332: Harmful if swallowed or if inhaled.  H314: Causes severe skin burns and eye damage.  H411: Toxic to aquatic life with long lasting effects.  P273: Avoid release to the environment.  P280: Wear protective gloves/ protective clothing/ eye protection/face protection/ hearing protection.  P303 + P361 + P353: IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water.  P304 + P340 + P310: IF INHALED: Remove person to fresh air and keep comfortable for breathing. Immediately call a POISON CENTER/ doctor.  P305 + P351 + P338 + P310: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/doctor.  P391 Collect spillage.  593-84-0 Guanidinium thiocyanate  9002-92-0 Polidocanol  3483-12-3 (R*,R*)-1,4-dimercaptobutane-2,3-diol</p>
<b>cobas® omni Wash Reagent (WASH)</b> Store at 15–30°C (P/N 06997503190)	Sodium citrate dihydrate, 0.1% methyl-4 hydroxybenzoate	4.2 L	Not applicable

\* Product safety labeling primarily follows EU GHS guidance

\*\*Hazardous substance

## Reagent storage requirements

Reagents shall be stored and will be handled as specified in Table 5, Table 6 and Table 7.

When reagents are not loaded on the **cobas®** 5800 system or **cobas®** 6800/8800 systems, store them at the corresponding temperature specified in Table 5.

**Table 5** Reagent storage (when reagent is not on the system)

Reagent	Storage temperature
<b>cobas®</b> TV/MG	2–8°C
<b>cobas®</b> TV/MG Positive Control Kit	2–8°C
<b>cobas®</b> Buffer Negative Control Kit	2–8°C
<b>cobas®</b> omni Lysis Reagent	2–8°C
<b>cobas®</b> omni MGP Reagent	2–8°C
<b>cobas®</b> omni Specimen Diluent	2–8°C
<b>cobas®</b> omni Wash Reagent	15–30°C

## Reagent handling requirements for cobas® 5800 system or cobas® 6800/8800 systems

Reagents loaded onto the **cobas®** 5800 system or **cobas®** 6800/8800 systems are stored at appropriate temperatures and their expiration is monitored and enforced by the system. The system allows reagents to be used only if all of the reagent handling conditions shown in Table 6, Table 7 and Table 8 are met. The system automatically prevents use of expired reagents. Remaining open-kit stability and number of kit uses information for assay specific reagents is accessible through the system user interface.

**Table 6** Reagent expiry conditions monitored and enforced by the **cobas®** 5800 systems

Reagent	Open-kit stability	Number of kit uses	On-board stability
<b>cobas®</b> TV/MG	90 days from first usage	40	36 days from loading
<b>cobas®</b> TV/MG Positive Control Kit	single use vial	16	36 days from loading
<b>cobas®</b> Buffer Negative Control Kit	single use vial	16	36 days from loading

**Table 7** Reagent expiry conditions monitored and enforced by the cobas® 6800/8800 systems

Reagent	Open-kit stability	Number of kit uses	On-board stability (outside on board refrigerator)
cobas® TV/MG	90 days from first usage	40	40 hours from loading
cobas® TV/MG Positive Control Kit	single use vial	16	10 hours from loading
cobas® Buffer Negative Control Kit	single use vial	16	10 hours from loading

Table 8 shows the open-kit stability of the cobas® omni reagents. Prior to each run, the system verifies the open-kit stability and ensures sufficient fill volume. Therefore, these reagents have no number of kit uses or on-board stability assigned.

**Table 8** cobas® omni reagent expiry condition enforced by the cobas® 5800/6800/8800 systems

Reagent	Open-kit stability
cobas® omni Lysis Reagent	30 days from loading
cobas® omni MGP Reagent	30 days from first usage
cobas® omni Specimen Diluent	30 days from loading
cobas® omni Wash Reagent	30 days from loading

## Additional materials required for cobas® 5800/6800/8800 systems

**Table 9** Material for use on **cobas®** 5800/6800/8800 systems

Material	P/N
<b>cobas®</b> <b>omni</b> Lysis Reagent	06997538190
<b>cobas®</b> <b>omni</b> MGP Reagent	06997546190
<b>cobas®</b> <b>omni</b> Specimen Diluent	06997511190
<b>cobas®</b> <b>omni</b> Wash Reagent	06997503190

**Table 10** Consumables for use on **cobas®** 5800 system\*

Material
<b>cobas®</b> <b>omni</b> Processing Plate 24
<b>cobas®</b> <b>omni</b> Liquid Waste Plate 24
<b>cobas®</b> <b>omni</b> Amplification Plate 24
Tip CORE TIPS with Filter, 1ml
Tip CORE TIPS with Filter, 300µL
<b>cobas®</b> <b>omni</b> Liquid Waste Container
Solid Waste Bag or Solid Waste Bag With insert
16-position tube S-carrier complete
5-position Rack Carrier
Cell Collection Media Carrier

\*For Part Numbers please refer to the **cobas®** 5800 system User Assistance.

**Table 11** Consumables for use on **cobas®** 6800/8800 systems\*

Material
<b>cobas®</b> <b>omni</b> Processing Plate
<b>cobas®</b> <b>omni</b> Amplification Plate
<b>cobas®</b> <b>omni</b> Pipette Tips
<b>cobas®</b> <b>omni</b> Liquid Waste Container
Solid Waste Bag and Solid Waste Container or Solid Waste Bag With Insert and Kit Drawer
STD-Rack. re-run R001-R025 PINK

\*For Part Numbers please refer to the **cobas®** 6800/8800 systems User Assistance.

## Instrumentation and software required

The **cobas®** 5800 software, the **cobas®** 6800/8800 systems software and **cobas®** TV/MG analysis package (ASAP) for **cobas®** 5800/6800/8800 systems shall be installed on the instrument(s).

For **cobas®** 5800 and the **cobas®** 6800/8800 systems with software 2.0 or higher, the x800 Data Manager software and PC (or server) will be provided with the system.

For the **cobas®** 6800/8800 systems with software version 1.4, the Instrument Gateway (IG) server will be provided with the system.

**Table 12** Instrumentation

Equipment	P/N
<b>cobas®</b> 5800 system	08707464001
<b>cobas®</b> 6800 system	05524245001 and 09575154001
<b>cobas®</b> 8800 system	05412722001 and 09575146001
Sample Supply Module for <b>cobas®</b> 6800/8800 systems	06301037001 and 09936882001

Refer to the **cobas®** 5800 system or **cobas®** 6800/8800 systems User Assistance for additional information.

## Additional materials required for sample collection for cobas® TV/MG

**Table 13** Specimen collection kits used with **cobas®** TV/MG

Collection Kit	P/N
<b>cobas®</b> PCR Media Kit	06466281190
<b>cobas®</b> PCR Urine Sample Kit	05170486190
<b>cobas®</b> PCR Media Uni Swab Sample Kit	07958030190
<b>cobas®</b> PCR Media Dual Swab Sample Kit	07958021190
ThinPrep Pap Test Physician's Kit (500 vials & Broom-like collection devices)	Hologic: 70136-001
ThinPrep Pap Test Physician's Kit (500 vials & Cytobrush/spatula collection devices)	Hologic: 70136-002

**cobas®** TV/MG accepts the primary tube used for all **cobas®** PCR media swab and urine specimen types. Refer to the **cobas®** 5800 system or the **cobas®** 6800/8800 systems User Assistance for additional information for primary and secondary sample tubes accepted on the instruments.

Note: Contact your local Roche representative for a detailed order list for sample racks, racks for clotted tips and rack trays accepted on the instruments

## Additional materials required for sample aliquoting and sample loading for cobas® TV/MG

**Table 14** Additional material used with cobas® TV/MG for sample aliquoting and loading

Material	P/N
cobas® PCR Media Secondary Tube Kit	07958048190
cobas® PCR Media Tube Replacement Cap Kit	07958056190
Replacement Caps for PreservCyt® Vials	08037230190
cobas® PCR Media Disposable Tube Stand (Optional)	07958064190
MPA RACK 16 MM LIGHT GREEN 7001-7050 <sup>a,b,c</sup>	03143449001
RD5 RACK – RD Standard rack 0001-0050 LR <sup>a,b,c</sup>	11902997001

<sup>a</sup> RD5 or MPA racks are required in combination with the 5-position Rack Carrier on the cobas® 5800 system.

<sup>b</sup> MPA 16mm rack or 16-position tube carrier are the preferred racks for use with samples collected in cobas® PCR Media tubes.

<sup>c</sup> MPA and RD5 racks identified here are example materials and part numbers. Please contact your local Roche representative for a detailed order list for sample racks and rack carriers accepted on the instruments.

## Precautions and handling requirements

### Warnings and precautions

As with any test procedure, good laboratory practice is essential to the proper performance of this assay. Due to the high sensitivity of this test, care should be taken to keep reagents and amplification mixtures free of contamination.

- For in vitro diagnostic use only.
- All patient samples should be handled as if infectious, using good laboratory procedures as outlined in Biosafety in Microbiological and Biomedical Laboratories and in the CLSI Document M29-A4.<sup>18,19</sup> Only personnel proficient in handling infectious materials and the use of cobas® TV/MG and cobas® 5800 system or cobas® 6800/8800 systems should perform this procedure.
- All human-sourced materials should be considered potentially infectious and should be handled with universal precautions. If spillage occurs, immediately disinfect with a freshly prepared solution of 0.5% sodium or potassium hypochlorite in distilled or deionized water or follow appropriate site procedures.
- Do not freeze any samples.
- Use only supplied or specified required consumables to ensure established test performance.
- Safety Data Sheets (SDS) are available on request from your local Roche representative.
- Closely follow procedures and guidelines provided to ensure that the test is performed correctly. Any deviation from the procedures and guidelines may affect established test performance.
- False positive results may occur if carryover of samples is not adequately controlled during sample handling and processing.
- cobas® PCR Media (from primary specimen tube) contains guanidine hydrochloride. **Do not allow direct contact between guanidine hydrochloride and sodium or potassium hypochlorite or other highly reactive reagents such as acids or bases. These mixtures can release a noxious gas.** If liquid containing guanidine hydrochloride is spilled, clean with suitable laboratory detergent and water. If the spilled liquid contains potentially infectious

agents, **FIRST** clean the affected area with laboratory detergent and water, and then with at least 0.5% sodium or potassium hypochlorite.

- Inform your local competent authority and manufacturer about any serious incidents which may occur when using this assay.

## Reagent handling

- Handle all reagents, controls, and samples according to good laboratory practice in order to prevent carryover of samples, reagents, or controls.
- Before use, visually inspect each reagent cassette, diluent, lysis reagent, and wash reagent to ensure that there are no signs of leakage. If there is any evidence of leakage, do not use that material for testing.
- **cobas® omni** Lysis Reagent contains guanidine thiocyanate, a potentially hazardous chemical. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur.
- Do not allow **cobas® omni** Lysis Reagent, which contains guanidine thiocyanate, to contact sodium or potassium hypochlorite solution. This mixture can produce a highly toxic gas.
- Expended control kits contain pierced vials with residual reagent; special care should be taken during disposal to avoid spills and contact.
- **cobas® TV/MG** kit, **cobas® TV/MG** Positive Control kit, **cobas® Buffer Negative Control** kit, **cobas® omni MGP** Reagent, and **cobas® omni** Specimen Diluent contain sodium azide as a preservative. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur. If these reagents are spilled, dilute with water before wiping dry.
- Do not allow **cobas® omni** Lysis Reagent, which contains guanidine thiocyanate, to contact sodium or potassium hypochlorite solution. This mixture can produce a highly toxic gas.
- Dispose of all materials that have come in contact with samples and reagents in accordance with country, state, and local regulations.

## Good laboratory practice

- Do not pipette by mouth.
- Do not eat, drink, or smoke in designated work areas.
- Wear laboratory gloves, laboratory coats, and eye protection when handling samples and reagents. Avoid contaminating gloves when handling samples and controls. Gloves must be changed between handling samples and **cobas® TV/MG**, **cobas® TV/MG** Positive Control Kit, **cobas® Buffer Negative Control** Kit, and **cobas® omni** reagents to prevent contamination.
- Wash hands thoroughly after handling samples and reagents, and after removing the gloves.
- Thoroughly clean and disinfect all laboratory work surfaces with a freshly prepared solution of 0.5% sodium or potassium hypochlorite in distilled or deionized water. Follow by wiping the surface with 70% ethanol.
- If spills occur on the **cobas® 5800** instrument or **cobas® 6800/8800** instruments, follow the instructions in the **cobas® 5800** system or **cobas® 6800/8800** systems User Assistance to properly clean and decontaminate the surface of instrument(s).

# Specimen collection, transport, and storage

**Note:** Handle all samples and controls as if they are capable of transmitting infectious agents.

## Specimen collection

Endocervical swab specimens collected with the **cobas**® PCR Media Dual Swab Sample Kit, vaginal swab specimens and meatal swab specimens collected with either the **cobas**® PCR Media Uni Swab Sample Kit or **cobas**® PCR Media Dual Swab Sample Kit, male and female urine collected with the **cobas**® PCR Urine Sample Kit and cervical specimens collected in PreservCyt® Solution may be used with **cobas**® TV/MG (see Table13 for a list of all collection kits). Follow the instructions for collecting all swab and urine specimens in their respective collection kit IFU. Follow the manufacturer's instructions for collecting cervical specimens into PreservCyt® Solution.

## Specimen transport

All specimen types listed in Specimen Collection section can be transported at 2-30°C. Transportation of TV/MG specimens in **cobas**® PCR Media and PreservCyt® Solution must comply with country, federal, state and local regulations for the transport of etiologic agents.<sup>20</sup>

## Specimen storage

**Table 15** Summary of acceptable specimen storage conditions prior to testing with **cobas**® TV/MG

Specimen Type	2-8°C	15-30°C
Samples in <b>cobas</b> ® PCR Media	12 months	12 months
PreservCyt® in collection device or PreservCyt® aliquoted to secondary tubes	90 days  31 days	90 days  31 days

Note: PreservCyt® and **cobas**® PCR Media specimens should not be frozen.

## Male and female urine specimens

- Use only the **cobas**® PCR Urine Sample Kit to collect urine specimens for **cobas**® TV/MG. **cobas**® TV/MG has not been validated for use with other urine collection devices or media types. Using **cobas**® TV/MG with other urine collection devices or other media types may lead to false negative, false positive, and/or invalid results.
- To avoid cross contamination of processed specimens, additional caps for **cobas**® PCR Media tubes in an alternate color (neutral; see **Additional materials required for sample aliquoting and sample loading for cobas**® TV/MG) should be used to recap specimens after processing.
- Untested urine specimens must show the top of the liquid level between the two black lines on the **cobas**® PCR Media tube label window. If the liquid level is above or below these lines, the specimen has not been collected properly and cannot be used for testing.
- If additional testing is required, ensure that there is at least 1.2 mL of specimen remaining the in **cobas**® PCR Media tube.



## Endocervical and vaginal specimens

- The presence of mucus in endocervical and cervical specimens may cause processing delays due to clotting. Mucus free specimens are required for optimal test performance. Use the large woven polyester swab in the **cobas®** PCR Media Dual Swab Sample Kit or an equivalent device to remove cervical secretions and discharge before obtaining the endocervical or cervical specimen.
- Use only the flocked swab in the **cobas®** PCR Media Dual Swab Sample Kit to collect endocervical specimens. Use only the woven polyester swab in either the **cobas®** PCR Media Uni Swab Sample Kit or the **cobas®** PCR Media Dual Swab Sample Kit to collect vaginal swab specimens. **cobas®** TV/MG has not been validated for use with other swab collection devices or media types. Using **cobas®** TV/MG with other swab collection devices or media types may lead to false negative, false positive, and/or invalid results.
- To avoid cross contamination of processed specimens, additional caps for **cobas®** PCR Media tubes in an alternate color (neutral; see **Additional materials required for sample aliquoting and sample loading for cobas® TV/MG**) should be used to recap specimens after processing.
- All swab specimens containing a single swab in the **cobas®** PCR Media tube can be directly processed on the **cobas®** 5800 system or **cobas®** 6800/8800 systems. If desired, the swab may be removed before the specimen tube is loaded onto the instrument, however utmost care must be exercised to avoid cross contamination.
- A properly collected swab specimen should have a single swab with the shaft broken at the scoreline. Swab shafts which are broken above the score line will appear longer than normal and may also be bent over to fit into the **cobas®** PCR Media tube. This can create an obstruction to the pipetting system which may cause the loss of sample, test results and/or mechanical damage to the instrument. In the event that a swab specimen has an improperly broken shaft, remove the swab prior to sample processing on the **cobas®** 5800 system or **cobas®** 6800/8800 systems. Use caution when disposing of specimen swabs; avoid splashing or touching swabs to other surfaces during disposal to prevent contamination.
- Incoming primary swab specimen tubes with no swabs or with two swabs have not been collected according to the instructions in their respective collective kit IFU and should not be tested.
- Occasionally, incoming swab specimens contain excessive mucus which may induce a pipetting error (e.g., clot or other obstruction) on the **cobas®** 5800 system or **cobas®** 6800/8800 systems. Prior to retesting of specimens that exhibited clots during initial processing, remove and discard the swab, then re-cap and vortex these specimens for 30 seconds to disperse the excess mucus.
- Swab specimens can be assayed twice on the **cobas®** 5800 system or **cobas®** 6800/8800 systems while the swab is in the collection tube. If additional testing is required, or if the first test fails due to specimen pipetting error (e.g., clot or other obstruction), the swab must be removed and the remaining fluid must have a minimum volume of 1.0 mL.

## Meatal specimens

- Use only the woven polyester swab in either the **cobas®** PCR Media Uni Swab Sample Kit or the **cobas®** PCR Media Dual Swab Sample Kit to collect meatal swab specimens. **cobas®** TV/MG has not been validated for use with other swab collection devices or media types. Using **cobas®** TV/MG with other swab collection devices or media types may lead to false negative, false positive, and/or invalid results.
- To avoid cross contamination of processed specimens, additional caps for **cobas®** PCR Media tubes in an alternate color (neutral; see **Additional materials required for sample aliquoting and sample loading for cobas® TV/MG**) should be used to recap specimens after processing.
- All meatal swab specimens containing a single swab in the **cobas®** PCR Media tube can be directly processed on the **cobas®** 5800 system or **cobas®** 6800/8800 systems while the volume in the collection tube is greater than 1.5 mL. If desired, the swab may be removed before the specimen tube is loaded onto the instrument, however utmost care must be exercised to avoid cross contamination.
- A properly collected swab specimen should have a single swab with the shaft broken at the scoreline. Swab shafts which are broken above the score line will appear longer than normal and may also be bent over to fit into the **cobas®** PCR Media tube. This can create an obstruction to the pipetting system which may cause the loss of sample, test results and/or mechanical damage to the instrument. In the event that a swab specimen has an improperly broken shaft, remove the swab prior to sample processing on the **cobas®** 5800 system or **cobas®** 6800/8800 systems. Use caution when disposing of specimen swabs; avoid splashing or touching swabs to other surfaces during disposal to prevent contamination.
- Incoming primary swab specimen tubes with no swabs or with two swabs have not been collected according to the instructions in their respective collective kit IFU and should not be tested.
- Meatal Swab specimens can be assayed twice on the **cobas®** 5800 system or **cobas®** 6800/8800 systems while the swab is in the collection tube. If additional testing is required, or if the first test fails due to specimen pipetting error (e.g., clot or other obstruction), the swab must be removed and the remaining fluid must have a minimum volume of 1.2 mL.

## Cervical specimens in PreservCyt® Solution

**cobas®** TV/MG is validated for use with cervical specimens collected in PreservCyt® Solution. **cobas®** TV/MG has not been validated for use with cervical specimens obtained in other media types. Using **cobas®** TV/MG with other media types may lead to false negative, false positive, and/or invalid results.

### **cobas®** 5800 system

- The **cobas®** 5800 system may process cervical specimen in PreservCyt® Solution directly out of their primary containers with a proper barcode or out of a properly barcoded **cobas®** PCR Media Secondary Tube (see **cobas®** 5800/6800/8800 systems section below for optional aliquoting instructions for **cobas®** 5800 system).
- With clean gloved hands, vortex the capped primary vial for **10 seconds** immediately **prior** to loading.
- Uncap the primary vial and place on a Cell Collection Media Carrier
- For primary vial loading, the minimum volume required in the PreservCyt® Solution primary containers is 3.0 mL.

## cobas® 5800/6800/8800 systems

- Cervical specimens in PreservCyt® Solution should be aliquoted into cobas® PCR Media Secondary Tubes as follows, for processing on the cobas® 5800 system or cobas® 6800/8800 systems:
  1. Prepare a barcoded cobas® PCR Media Secondary Tube for each PreservCyt® specimen to be tested.
  2. With clean gloved hands, vortex each PreservCyt® primary specimen vial for 10 seconds immediately prior to transfer.
  3. Uncap a primary vial and transfer at least 1.0 mL but no more than 4.0 mL into the prepared barcoded secondary tube from step 1.
    - *Always use caution when transferring specimens from primary containers to secondary tube.*
    - *Always use a new pipette tip for each specimen.*
    - *Always use pipettors with aerosol-barrier or positive-displacement tips to handle specimens.*
    - *To avoid cross contamination, additional caps for these tubes in an alternate color (neutral; see **Additional materials required for sample aliquoting and sample loading for cobas® TV/MG**) should be used to recap these specimens after processing.*
    - *Transfer tube to a rack if testing is to be performed shortly after or cap the secondary tube if testing will be performed at a future time.*
  4. Re-cap the primary vial with a replacement cap before moving to the next specimen. Store the primary vial upright.
  5. Only racks of uncapped tubes should be loaded on to the systems for TV/MG testing.
- Aliquots of the primary specimen must contain a minimum volume of 1.0 mL.

## Instructions for use

### Procedural notes

- Do not use cobas® TV/MG, cobas® TV/MG Positive Control Kit, cobas® Buffer Negative Control Kit, or cobas® omni reagents after their expiry dates.
- Do not reuse consumables. They are for one-time use only.
- cobas® TV/MG can be run with a minimum required sample volume of 1.0 mL for (endocervical and vaginal swabs) and cervical specimens in PreservCyt® (transferred to cobas® PCR Media Tube), and 1.2 mL for meatal swab and urine specimens.
- PreservCyt® specimens may be uncapped and run from primary vials on the cobas® 5800 system with a minimum required sample volume of 3mL.

### Running cobas® TV/MG on cobas® 5800/6800/8800 systems

- The operation of the instrument is described in detail in the cobas® 5800/6800/8800 systems User Assistance. Figure 1 and Figure 2 below summarizes the procedure.
- Refer to the cobas® 5800 system or cobas® 6800/8800 systems User Assistance for proper maintenance of instruments.
- Swab (Female and Meatal) and Urine specimens should be uncapped and loaded directly onto racks for processing on the cobas® 5800 system or cobas® 6800/8800 systems.
- Note: Use slow and steady movements when loading and unloading the Cell Collection Medium Carrier (holding

primary vials) to avoid splashing of specimens.

- PreservCyt® specimens may be aliquoted into barcoded 13 mL round-bottom **cobas**® PCR Media Secondary tubes for processing on the **cobas**® 5800 system or **cobas**® 6800/8800 systems. Refer to the preparation instructions for cervical specimens found in section: “Cervical specimens in PreservCyt® Solution”.
- Optionally, PreservCyt® specimens may be uncapped and run from primary vials on the **cobas**® 5800 system.
- A single run can have any combination of specimens (Swab (Female and Meatal), Urine, and PreservCyt®) and each specimen can be tested for either TV/MG, TV, or MG.
- Specimens collected in **cobas**® PCR Media or PreservCyt® Solution should be processed using the sample type selection in the user interface (UI) of the **cobas**® TV/MG as described in Table 16.
- Ensure that specimen barcode labels on sample tubes are visible through the openings on the side of sample carriers. Refer to the **cobas**® 5800 system or **cobas**® 6800/8800 systems User Assistance for proper barcode specifications and additional information on loading sample tubes.

**Table 16** Sample type selection in the user interface of the **cobas**® 5800/6800/8800 systems

Specimen		Collection kit type	Process as Sample Type
Female	Vaginal swab	<b>cobas</b> ® PCR Media Uni or Dual Swab Sample Kit	<b>Swab</b>
	Endocervical swab	<b>cobas</b> ® PCR Media Dual Swab Sample Kit	<b>Swab</b>
	Urine	<b>cobas</b> ® PCR Urine Sample Kit or <b>cobas</b> ® PCR Media Kit	<b>Urine</b>
	Cervical specimens	PreservCyt® Solution (ThinPrep)	<b>PreservCyt®</b>
Male	Urine	<b>cobas</b> ® PCR Urine Sample Kit or <b>cobas</b> ® PCR Media Kit	<b>Urine</b>
	Meatal swab	<b>cobas</b> ® PCR Media Uni or Dual Swab Sample Kit	<b>Meatal Swab*</b>

\*For manual and rack-based ordering: Make sure to select “Meatal Swab”, not “Swab”, as the sample type for Meatal Swab specimens. Swab sample type includes only: vaginal and endocervical swab specimens.

**Figure 1** cobas® TV/MG test procedure on cobas® 5800 system

<b>1</b>	Log onto the system
<b>2</b>	<p>Loading specimens onto the system</p> <ul style="list-style-type: none"> <li>For each urine or swab in <b>cobas®</b> PCR Media <ul style="list-style-type: none"> <li>Uncap tube</li> <li>Transfer tube directly to rack</li> </ul> </li> <li>For each primary PreservCyt® specimen vial: <ul style="list-style-type: none"> <li>If loading primary vial: <ul style="list-style-type: none"> <li>Vortex for 10 seconds</li> <li>Uncap vial</li> <li>Transfer vial to rack</li> </ul> </li> <li>If loading secondary tube: <ul style="list-style-type: none"> <li>Vortex for 10 seconds</li> <li>Aliquot a minimum of 1 mL of PreservCyt® specimen into a <b>cobas®</b> PCR Media Secondary tube</li> <li>Transfer tube to rack</li> </ul> </li> </ul> </li> <li>Load sample rack</li> </ul> <p>Confirm samples have been accepted into the system</p> <p>Order Tests</p> <ul style="list-style-type: none"> <li>Choose "Swab" for ordering endocervical and vaginal swab specimens collected in <b>cobas®</b> PCR Media</li> <li>Choose "Urine" for ordering male and female urine specimens collected in <b>cobas®</b> PCR Media</li> <li>Choose "Meatal Swab" for ordering meatal swab specimens collected in <b>cobas®</b> PCR Media</li> <li>Choose "PreservCyt" for ordering PreservCyt® Solution (cervical specimens)</li> </ul> <p>Choose the Test name</p>
<b>3</b>	<p>Refill reagents and consumables as prompted by the system</p> <ul style="list-style-type: none"> <li>Load test specific reagent cassette</li> <li>Load control mini racks</li> <li>Load processing tips</li> <li>Load elution tips</li> <li>Load processing plates</li> <li>Load amplification plates</li> <li>Load Liquid waste plates</li> <li>Load MGP Reagent</li> </ul> <p>Refill Specimen Diluent Refill Lysis Reagent Refill Wash Reagent</p>
<b>4</b>	Start the run by choosing the Start processing button on the user interface, all subsequent runs will start automatically if not manually postponed
<b>5</b>	Review and export results
<b>6</b>	<p>Remove sample tubes. If needed, cap any sample tubes meeting the minimum volume requirements for future use.</p> <p>Clean up instrument</p> <ul style="list-style-type: none"> <li>Unload empty test specific reagent cassette(s)</li> <li>Unload empty control mini racks</li> <li>Empty amplification plate drawer</li> <li>Empty liquid waste</li> <li>Empty solid waste</li> </ul>

**Figure 2** cobas® TV/MG test procedure on cobas® 6800/8800 systems

1	<p>Log onto the system Press Start to Prepare the system Order Tests</p> <ul style="list-style-type: none"> <li>• Choose “Swab” for ordering endocervical and vaginal swab specimens collected in <b>cobas®</b> PCR Media</li> <li>• Choose “Urine” for ordering male and female urine specimens collected in <b>cobas®</b> PCR Media</li> <li>• Choose “Meatal Swab” for ordering meatal swab specimens collected in <b>cobas®</b> PCR Media</li> <li>• Choose “PreservCyt” for ordering PreservCyt® Solution (cervical specimens)</li> <li>• Choose the Test</li> </ul>
2	<p>Refill reagents and consumables as prompted by the system</p> <ul style="list-style-type: none"> <li>• Load test specific reagent cassette</li> <li>• Load control cassettes</li> <li>• Load Pipette Tips</li> <li>• Load Processing Plates</li> <li>• Load MGP Reagent</li> <li>• Load Amplification Plates</li> <li>• Refill Specimen Diluent</li> <li>• Refill Lysis Reagent</li> <li>• Refill Wash Reagent</li> </ul>
3	<p>Loading specimens onto the system</p> <ul style="list-style-type: none"> <li>• For each primary Urine, Swab, or Meatal Swab in <b>cobas®</b> PCR Media <ul style="list-style-type: none"> <li>◦ Uncap tube</li> <li>◦ Transfer tube directly to rack</li> </ul> </li> <li>• For each primary PreservCyt® specimen vial: <ul style="list-style-type: none"> <li>◦ Vortex for 10 seconds</li> <li>◦ Aliquot a minimum of 1 mL of PreservCyt® specimen into a 13 mL round-bottom secondary tube</li> <li>◦ Transfer tube to rack</li> </ul> </li> <li>• Load sample rack and clot tip racks into the sample supply module</li> <li>• Confirm samples have been accepted into the transfer module</li> </ul>
4	Start run
5	Review and export results
6	<p>Remove and cap any sample tubes meeting the minimum volume requirements if needed for future use</p> <p>Clean up instrument</p> <ul style="list-style-type: none"> <li>• Unload empty control cassettes</li> <li>• Empty amplification plate drawer</li> <li>• Empty liquid waste</li> <li>• Empty solid waste</li> </ul>

## Results

The cobas® 5800 system and cobas® 6800/8800 systems automatically detects and discriminates TV and/or MG DNA simultaneously for samples and controls, displaying test validity, overall results, as well as individual target results.

### Quality control and validity of results on cobas® 5800 system and cobas® 6800/8800 systems with software version 2.0 or higher

- One cobas® Buffer Negative Control [(-) Ctrl] and one cobas® TV/MG Positive Control [TV/MG (+) C] must be processed at least every 72 hours or with every new kit lot. Positive and/or negative controls can be scheduled more frequently based on laboratory procedures and/or local regulations.
- The results of the controls are shown in the “Controls” app of the software.
- In the software and/or report, check for flags to ensure the validity of the corresponding test results (refer to the x800 Data Manager User Assistance for a ‘List of flag codes’).
- The controls are valid if no flags appear for either control.
- Controls are marked with ‘Valid’ in the column “Control result” if the respective targets of the control are reported valid. Controls are marked with ‘Invalid’ in the column “Control result” if the respective targets of the control are reported invalid.
- Controls marked with ‘Invalid’ show a flag in the “Flags” column. More information on why the control is reported invalid including flag information will be shown in the detail view.

If one of the controls is invalid, repeat testing of all controls and all associated samples is required.

Validation of results is performed automatically by the instrument software based on control results.

**NOTE:** The cobas® 5800 system and the cobas® 6800/8800 systems with software version 2.0 will be delivered with the standard setting of running a set of controls (positive and negative) with every run, but can be configured to a less frequent scheduling up to every 72 hours based on laboratory procedures and/or local regulations. Please contact your Roche service engineer and/or Roche customer technical support for more information.

### Quality control and validity of results on cobas® 6800/8800 systems with software version 1.4


- One cobas® Buffer Negative Control [(-) Ctrl] and one cobas® TV/MG Positive Control [TV/MG (+) C] are processed with each batch of a requested result type.
- In the software and/or report, check for flags and their associated results to ensure batch validity.
- All flags are described in the cobas® 6800/8800 systems User Assistance.
- The batch is valid if no flags appear for all controls. If the batch is invalid, repeat testing of the entire batch is required.

Validation of results is performed automatically by the instrument software based on control results.

## Interpretation of results on the cobas® 5800 system and cobas® 6800/8800 systems with software version 2.0 or higher

The results of the samples are shown in the “Results” app of the software. Result display examples are shown in Figure 3.

**Figure 3** Example of cobas® TV/MG results display for cobas® 5800 system and cobas® 6800/8800 systems with software version 2.0 or higher

Sample ID*	Test	Control results	Flag**	Result
TV/MG_01	TV/MG	Valid		TV Negative MG Negative
MG 01_	MG	Valid		MG Positive (Ct 36.52)
TV/MG_02	TV/MG	Valid		TV Invalid MG Invalid
TV 01	TV	Valid		TV Negative
TV/MG_03	TV/MG	Valid		TV Positive (Ct 35.44) MG positive (Ct 36.00)

\* Table applies for all sample types used.

\*\* The result overview shows a flag symbol in case of invalid results. Detailed flag descriptions are available in the result details.

Check each individual sample for flags in the software and/or report. The result interpretation should be as follows:

- Samples associated with valid controls are shown as ‘Valid’ in the “Control result” column.
- Samples associated with a failed control are shown as ‘Invalid’ in the “Control result” column.
- If the associated controls of a sample result are invalid, a specific flag will be added to the sample result as follows:
  - Q05D : Result validation failure because of an invalid positive control
  - Q06D : Result validation failure because of an invalid negative control
- The values in “Results” column for individual sample target result should be interpreted as shown in Figure 4, Figure 5 and Figure 6 below.
- If one or more sample targets are marked with “Invalid” the software shows a flag in the “Flags” column. More information on why the sample target(s) is reported invalid including flag information is shown in the detail view.
- Invalid results for one or more target combinations are possible with the TV/MG result request and are reported out specifically for each target. Refer to retesting instructions for the respective specimen type.
- Results of this test should only be interpreted in conjunction with information available from clinical evaluation of the patient and patient history.

## Interpretation of results on the cobas® 6800/8800 systems with software version 1.4

Result display examples are shown in Figure 4, Figure 5, and Figure 6, respectively.



**Figure 4** Example of **cobas®** TV/MG results display for TV/MG result request for **cobas®** 6800/8800 systems with software version 1.4

Test	Sample ID	Valid	Flags	Sample type	Overall result	Target 1	Target 2
TV/MG	PC_TVMGNeg_01	NA		PreservCyt®	<b>NA</b>	TV Negative	MG Negative
TV/MG	PC_TVMGInv_01	NA	Y40T	PreservCyt®	<b>NA</b>	Invalid	Invalid
TV/MG	UR_TVMGNegPos_B1	NA		Urine	<b>NA</b>	TV Negative	MG Positive
TV/MG	UR_TVMGPos_B2	NA		Urine	<b>NA</b>	TV Positive	MG Positive
TV/MG	MS_TVMGNeg_01	NA		Meatal Swab	<b>NA</b>	TV Negative	MG Negative
TV/MG	MS_TVMGPosNeg_A6	NA		Meatal Swab	<b>NA</b>	TV Positive	MG Negative
TV/MG	SB_TVMGPosInv_01	NA	C01H2	Swab	<b>NA</b>	TV Positive	Invalid
TV/MG	SB_TVMGInvPos_A2	NA	C01H1	Swab	<b>NA</b>	Invalid	MG Positive
TV/MG	C161420284090428828404	Yes		(-) Ctrl	<b>Valid</b>	Valid	Valid
TV/MG	C161420284093009580264	Yes		TV/MG (+) C	<b>Valid</b>	Valid	Valid

**Figure 5** Example of **cobas®** TV results display for TV result request for **cobas®** 6800/8800 systems with software version 1.4

Test	Sample ID	Valid	Flags	Sample type	Overall result	Target 1	Target 2
TV	SB_TVInv_01	NA	Y40T	Swab	<b>NA</b>	Invalid	
TV	SB_TVNeg_01	NA		Swab	<b>NA</b>	TV Negative	
TV	UR_TVPos_A5	NA		Urine	<b>NA</b>	TV Positive	
TV	UR_TVNeg_01	NA		Urine	<b>NA</b>	TV Negative	
TV	PC_TVPos_A3	NA		PreservCyt®	<b>NA</b>	TV Positive	
TV	PC_TVNeg_01	NA		PreservCyt®	<b>NA</b>	TV Negative	
TV	MS_TVInv_01	NA	P02T	Meatal Swab	<b>NA</b>	Invalid	
TV	MS_TVNeg_01	NA		Meatal Swab	<b>NA</b>	TV Negative	
TV	C161420284093009580263	Yes		TV/MG (+) C	<b>Valid</b>	Valid	
TV	C161420284090428828403	Yes		(-) Ctrl	<b>Valid</b>	Valid	

Note: No results are shown under Target 2 because it is reserved for MG results.

**Figure 6** Example of **cobas®** MG results display for MG result request for **cobas®** 6800/8800 systems with software version 1.4

Test	Sample ID	Valid	Flags	Sample type	Overall result	Target 1	Target 2
MG	UR_MGVNeg_A1	NA		Urine	<b>NA</b>		MG Negative
MG	UR_MGNeg_01	NA		Urine	<b>NA</b>		MG Negative
MG	MS_MGInv_01	NA	Y40T	Meatal Swab	<b>NA</b>		Invalid
MG	MS_MGPos_A2	NA		Meatal Swab	<b>NA</b>		MG Positive
MG	PC_MGPos_B1	NA		PreservCyt®	<b>NA</b>		MG Positive
MG	PC_MGNeg_01	NA		PreservCyt®	<b>NA</b>		MG Negative
MG	SB_MGPos_A7	NA		Swab	<b>NA</b>		MG Positive
MG	SB_MGNeg_01	NA		Swab	<b>NA</b>		MG Negative
MG	C16142028409300950734	Yes		TV/MG (+) C	<b>Valid</b>		Valid
MG	C161420284090428828402	Yes		(-) Ctrl	<b>Valid</b>		Valid

Note: No results are shown under Target 1 because it is reserved for TV results.

For a valid batch, check each individual sample for flags in the **cobas®** 6800/8800 systems with software version 1.4 and/or report. The result interpretation should be as follows:

- A valid batch may include both valid and invalid sample results.
- The “Valid” and “Overall Result” columns are not applicable (NA) to sample results for the **cobas®** TV/MG and are marked with “NA”. Values reported in these columns are not applicable and **do not** impact the validity of results reported within individual Target Result columns.
- Reported target results for individual samples are valid unless indicated as “Invalid” within the individual target result column.
- Invalid results for one or more target combinations are possible with the TV/MG result request and are reported out specifically for each target. Refer to the retesting instructions for respective specimen type.
- Results of this test should only be interpreted in conjunction with information available from clinical evaluation of the patient and patient history.

## Interpretation of results for **cobas®** 5800/6800/8800 systems

Results and their corresponding interpretation for detecting TV and MG (Table 17), TV only (Table 18) and MG only (Table 19) are shown below.

**Table 17** cobas® TV/MG results and interpretation for the TV/MG result request

Result		Interpretation
TV Positive	MG Positive	All requested results were valid. Target signal detected for TV and MG DNA.
TV Positive	MG Negative	All requested results were valid. Target signal detected for TV DNA. No target signal detected for MG DNA.
TV Negative	MG Positive	All requested results were valid. No target signal detected for TV DNA. Target signal detected for MG DNA.
TV Negative	MG Negative	All requested results were valid. No target signal detected for TV or MG DNA.
TV Positive	Invalid	Not all requested results were valid. Target signal detected for TV DNA. TV result is valid. MG result is invalid. Original specimen should be re-tested to obtain valid MG results. If the result is still invalid, a new specimen should be obtained.
Invalid	MG Positive	Not all requested results were valid. TV result is invalid. Original specimen should be re-tested to obtain valid TV results. If the result is still invalid, a new specimen should be obtained. Target signal detected for MG DNA. MG result is valid.
TV Negative	Invalid	Not all requested results were valid. No target signal detected for TV DNA. TV result is valid. MG result is invalid. Original specimen should be re-tested to obtain valid MG results. If the result is still invalid, a new specimen should be obtained.
Invalid	MG Negative	Not all requested results were valid. TV result is invalid. Original specimen should be re-tested to obtain valid TV results. If the result is still invalid, a new specimen should be obtained. No target signal detected for MG DNA. MG result is valid.
Invalid	Invalid	Both TV and MG results are invalid. Original specimen should be re-tested to obtain valid TV and MG results. If the results are still invalid, a new specimen should be obtained.

**Table 18** cobas® TV/MG results and interpretation for the TV result request

Result	Interpretation
TV Positive	The requested result was valid. Target signal detected for TV DNA.
TV Negative	The requested result was valid. No target signal detected for TV DNA
Invalid	TV result is invalid. Original specimen should be re-tested to obtain valid TV results. If the result is still invalid, a new specimen should be obtained.

**Table 19** cobas® TV/MG results and interpretation for the MG result request

Result	Interpretation
MG Positive	The requested result was valid. Target signal detected for MG DNA.
MG Negative	The requested result was valid. No target signal detected for MG DNA
Invalid	MG result is invalid. Original specimen should be re-tested to obtain valid MG results. If the result is still invalid, a new specimen should be obtained.

## Procedural limitations

- Use of this product must be limited to personnel trained in the techniques of PCR and the use of the **cobas**® 5800 system or **cobas**® 6800/8800 systems.
- **cobas**® TV/MG has been evaluated only for use in combination with the **cobas**® TV/MG Positive Control Kit, **cobas**® Buffer Negative Control Kit, **cobas**® **omni** MGP Reagent, **cobas**® **omni** Lysis Reagent, **cobas**® **omni** Specimen Diluent, and **cobas**® **omni** Wash Reagent for use on the **cobas**® 5800 system or **cobas**® 6800/8800 systems.
- Reliable results depend on proper sample collection, storage and handling procedures.
- Products containing carbomer(s), including vaginal lubricants, creams and gels may interfere with the test and should not be used during or prior to collecting urogenital specimens. See Interference results (Table 24) for further details.
- **cobas**® TV/MG has been validated for use with male and female urine, clinician-instructed self-collected vaginal swab specimens, clinician-collected vaginal swab specimens, clinician-instructed self-collected meatal swab specimens, clinician-collected meatal swab specimens, and endocervical swab specimens, all collected in **cobas**® PCR Media (Roche Molecular Systems, Inc.) and cervical specimens collected in PreservCyt® Solution. Assay performance has not been established with other collection media and/or specimen types. Use of other collection media and/or specimen types may lead to false positive, false negative or invalid results.
- **cobas**® TV/MG has not been evaluated in patients younger than 14 years of age.
- Detection of *T. vaginalis* and *M. genitalium* is dependent on the number of organisms present in the specimen and may be affected by specimen collection methods, patient factors (i.e., age, history of STD, presence of symptoms), stage of infection and/or infecting *T. vaginalis* and *M. genitalium* strains.
- **cobas**® TV/MG for urine testing is recommended to be performed on first catch urine specimens (defined as the first 10 to 50 mL of the urine stream). The effects of other variables such as first-catch vs. mid-stream, post-douching, etc. have not been evaluated.
- The effects of other potential variables such as vaginal discharge, use of tampons, douching, etc. and specimen collection variables have not been evaluated.
- **cobas**® TV/MG has not been evaluated with patients who were currently being treated with antimicrobial agents active against TV or MG as well as patients with a history of hysterectomy.
- False negative or invalid results may occur due to polymerase inhibition. The Internal Control is included in **cobas**® TV/MG to help identify the specimens containing substances that may interfere with nucleic acid isolation and PCR amplification.
- The addition of AmpErase enzyme into the **cobas**® TV/MG Master Mix reagent enables selective amplification of target DNA; however, good laboratory practices and careful adherence to the procedures specified in this Instructions-For-Use document are necessary to avoid contamination of reagents.
- Though rare, mutations within the highly conserved regions of the genomic DNA of *T. vaginalis* or the genomic DNA of *M. genitalium* covered by **cobas**® TV/MG primers and/or probes may result in failure to detect the presence of the bacterium.
- Due to inherent differences between technologies, it is recommended that, prior to switching from one technology to the next; users perform method correlation studies in their laboratory to qualify technology differences.

# Non-clinical performance evaluation

## System equivalency

System equivalency of the cobas® 5800, cobas® 6800 and cobas® 8800 systems was demonstrated via performance studies. The data presented in this Instructions for Use support equivalent performance for all systems.

## Key performance characteristics

### Limit of Detection (LoD)

The limit of detection of cobas® TV/MG was determined by analysis of serial dilutions of two TV (RP - metronidazole susceptible and CDC085 - metronidazole resistant) and two different (MG37 and M30) MG strains. Panels of six to seven concentration levels plus a blank were tested over three lots of cobas® TV/MG test reagents, multiple runs, days, operators, and instruments.

The LoD for TV ranged from 0.02 cells/mL (TV strain CDC085 in meatal swab) to 0.16 cells/mL (RP strain in vaginal swab).

The LoD for MG ranged from 0.3 cp/mL (MG strain G37 in urine) to 3.2 cp/mL (MG strain M30 in vaginal swab).

### Inclusivity

The inclusivity of cobas® TV/MG was confirmed by testing eight TV (*C-1:NIH, 123414, 129155-8, CDC337, NYH 209, PRA-98, 801805, BACT-053LR01*) and five MG (*SEA-1, M2288, M2300, M2321, M2341*) strains. All TV strains were detected at or below 0.16 cells/mL and all MG strains at or below 3.2 cp/mL.

### Precision

In-house precision was examined using a panel composed of TV and MG cultures diluted into pooled negative urine stabilized in cobas® PCR Media, as well as in contrived matrices equivalent to vaginal and meatal swab specimens collected in cobas® PCR Media or in cervical specimens collected in PreservCyt® Solution. Sources of variability were examined with a panel consisting of four concentration levels, using three lots of cobas® TV/MG reagents and two instruments over a time course of 12 days and with a total of 24 runs. A description of the precision panels and the study performance positivity rates are shown in Table 20. All negative panel members tested negative throughout the study. Analysis of standard deviation and percent coefficient of variation of the Ct values from valid tests performed on positive panel members (see Table 21 and Table 22) yielded overall CV (%) ranges from 1.5% to 2.8% for TV and from 1.2% to 4.9% for MG.

**Table 20** Summary of within laboratory precision

Target Concentration		N Tested	N positive TV	N positive MG	Hit Rate		95% Confidence Interval			
							TV		MG	
TV	MG				TV	MG	Lower Limit	Upper Limit	Lower Limit	Upper Limit
Vaginal Swab collected in <b>cobas®</b> PCR Media										
Neg	Neg	72	0	0	0.0%	0.0%	0.0%	5.0%	0.0%	5.0%
0.06 cells/mL	1.2 cp/mL	72	48	61	66.7%	84.7%	54.6%	77.3%	74.3%	92.1%
0.24 cells/mL	4.8 cp/mL	71	69	70	97.2%	98.6%	90.2%	99.7%	92.4%	100.0%
0.73 cells/mL	14.4 cp/mL	72	72	72	100.0%	100.0%	95.0%	100.0%	95.0%	100.0%
Urine stabilized in <b>cobas®</b> PCR Media										
Neg	Neg	72	0	0	0.0%	0.0%	0.0%	5.0%	0.0%	5.0%
0.02 cells/mL	0.2 cp/mL	72	44	53	61.1%	73.6%	48.9%	72.4%	61.9%	83.3%
0.07 cells/mL	0.8 cp/mL	72	72	72	100.0%	100.0%	95.0%	100.0%	95.0%	100.0%
0.20 cells/mL	2.5 cp/mL	72	72	72	100.0%	100.0%	95.0%	100.0%	95.0%	100.0%
Meatal Swab collected in <b>cobas®</b> PCR Media										
Neg	Neg	72	0	0	0.0%	0.0%	0.0%	5.0%	0.0%	5.0%
0.01 cells/mL	0.1 cp/mL	72	37	41	51.4%	56.9%	39.3%	63.4%	44.7%	68.6%
0.05 cells/mL	0.5 cp/mL	72	71	69	98.6%	95.8%	92.5%	100.0%	88.3%	99.1%
0.16 cells/mL	1.6 cp/mL	72	72	72	100.0%	100.0%	95.0%	100.0%	95.0%	100.0%
Cervical specimens collected in PreservCyt® Solution										
Neg	Neg	72	0	0	0.0%	0.0%	0.0%	5.0%	0.0%	5.0%
0.03 cells/mL	0.3 cp/mL	72	39	41	54.2%	56.9%	42.0%	66.0%	44.7%	68.6%
0.11 cells/mL	1.1 cp/mL	72	69	68	95.8%	94.4%	88.3%	99.1%	86.4%	98.5%
0.33 cells/mL	3.3 cp/mL	72	72	72	100.0%	100.0%	95.0%	100.0%	95.0%	100.0%

**Table 21** Overall mean, standard deviations and coefficients of variation (%) for cycle threshold, TV positive panels

Target Concentration	Hit Rate	Mean Ct	Within run		Between run		Between day		Between instrument		Between lot		Total	
TV			SD	CV%	SD	CV%	SD	CV%	SD	CV%	SD	CV%	SD	CV%
Vaginal Swab collected in <b>cobas®</b> PCR Media														
0.06 cells/mL	66.7%	37.6	0.98	2.6	0.0	0.0	0.0	0.0	0.26	0.7	0.22	0.7	1.04	2.8
0.24 cells/mL	97.2%	36.5	0.62	1.7	0.22	0.6	0.00	0.0	0.60	1.6	0.19	0.5	0.91	2.5
0.73 cells/mL	100.0%	35.5	0.38	1.1	0.05	0.2	0.03	0.1	0.74	2.1	0.15	0.4	0.85	2.4
Urine stabilized in <b>cobas®</b> PCR Media														
0.02 cells/mL	61.1%	37.7	0.86	2.3	0.00	0.0	0.25	0.7	0.00	0.0	0.10	0.3	0.90	2.4
0.07 cells/mL	100.0%	36.7	0.62	1.7	0.31	0.8	0.18	0.5	0.11	0.3	0.16	0.4	0.74	2.0
0.20 cells/mL	100.0%	35.6	0.36	1.0	0.09	0.3	0.14	0.4	0.33	0.9	0.11	0.3	0.53	1.5
Meatal Swab collected in <b>cobas®</b> PCR Media														
0.01 cells/mL	51.4%	38.0	0.81	2.1	0.31	0.8	0.00	0.0	0.02	0.1	0.00	0.0	0.87	2.3
0.05 cells/mL	98.6%	36.9	0.76	2.1	0.00	0.0	0.13	0.4	0.00	0.0	0.00	0.0	0.77	2.1
0.16 cells/mL	100.0%	35.9	0.46	1.3	0.00	0.0	0.00	0.0	0.47	1.3	0.15	0.4	0.68	1.9
Cervical specimens collected in PreservCyt® Solution														
0.03 cells/mL	54.2%	37.6	0.65	1.7	0.30	0.8	0.29	0.8	0.42	1.1	0.00	0.0	0.87	2.3
0.11 cells/mL	95.8%	36.7	0.69	1.9	0.28	0.8	0.00	0.0	0.50	1.4	0.06	0.2	0.90	2.4
0.33 cells/mL	100.0%	34.6	0.64	1.8	0.15	0.4	0.00	0.0	0.64	1.8	0.00	0.0	0.92	2.6

**Table 22** Overall mean, standard deviations and coefficients of variation (%) for cycle threshold, MG positive panels

Target Concentration	Hit Rate	Mean Ct	Within run		Between run		Between day		Between instrument		Between lot		Total	
MG			SD	CV%	SD	CV%	SD	CV%	SD	CV%	SD	CV%	SD	CV %
Vaginal Swab collected in <b>cobas®</b> PCR Media														
1.2 cp/mL	84.7%	37.2	1.29	3.5	0.00	0.0	0.00	0.0	0.98	2.6	0.00	0.0	1.62	4.3
4.8 cp/mL	98.6%	35.6	0.56	1.6	0.00	0.0	0.16	0.5	0.71	2.0	0.05	0.1	0.92	2.6
14.4 cp/mL	100.0%	34.7	0.26	0.7	0.00	0.0	0.05	0.1	0.73	2.1	0.10	0.3	0.78	2.3
Urine stabilized in <b>cobas®</b> PCR Media														
0.2 cp/mL	73.6%	37.9	1.19	3.2	0.00	0.0	0.00	0.0	0.00	0.0	0.32	0.8	1.24	3.3
0.8 cp/mL	100.0%	36.3	0.66	1.8	0.21	0.6	0.00	0.0	0.25	0.7	0.20	0.6	0.76	2.1
2.5 cp/mL	100.0%	35.2	0.25	0.7	0.18	0.5	0.00	0.0	0.28	0.8	0.09	0.3	0.42	1.2
Meatal Swab collected in <b>cobas®</b> PCR Media														
0.1 cp/mL	56.9%	38.1	1.55	4.1	0.37	1.0	0.00	0.0	0.95	2.5	0.00	0.0	1.85	4.9
0.5 cp/mL	95.8%	37.0	0.78	2.1	0.00	0.0	0.00	0.0	0.39	1.1	0.00	0.0	0.87	2.4
1.6 cp/mL	100.0%	35.7	0.33	0.9	0.00	0.0	0.00	0.0	0.32	0.9	0.18	0.5	0.50	1.4
Cervical specimens collected in PreservCyt® Solution														
0.3 cp/mL	56.9%	37.9	1.20	3.2	0.97	2.6	0.07	0.2	0.50	1.3	0.67	1.8	1.75	4.6
1.1 cp/mL	94.4%	36.5	0.87	2.4	0.52	1.4	0.00	0.0	0.76	2.1	0.15	0.4	1.27	3.5
3.3 cp/mL	100.0%	35.2	0.46	1.3	0.00	0.0	0.09	0.3	0.59	1.7	0.00	0.0	0.75	2.1

## Analytical specificity/cross reactivity

A panel of 102 bacteria, fungi and viruses, including those commonly found in the male and female urogenital tract, were tested with **cobas®** TV/MG to assess analytical specificity. The organisms listed in Table 23 were spiked at concentrations of approximately  $1 \times 10^6$  units/mL for bacteria and approximately  $1 \times 10^5$  units/mL for viruses into pooled negative urine stabilized in **cobas®** PCR Media. Testing was performed with each potential interfering organism in absence and presence of TV and MG target (spiked at approximately  $3 \times \text{LoD}$ ). None of the organisms tested interfered with the test performance by generating false positive results. Detection of TV and MG target was not affected by organisms tested except *Trichomonas tenax* at concentration levels  $> 1\text{E}+04$  CFU/mL. *Trichomonas tenax* is a commensal of the oral cavity.

**Table 23** Microorganisms tested for analytical specificity/cross reactivity

Microorganism	Concentration	Microorganism	Concentration
<i>Acholeplasma laidlawii</i>	1.0E+06 CFU/mL	<i>Klebsiella oxytoca</i>	1.0E+06 CFU/mL
<i>Acholeplasma oculi</i>	1.0E+06 CFU/mL	<i>Klebsiella pneumoniae</i>	1.0E+06 CFU/mL
<i>Achromobacter xerosis</i>	1.0E+06 CFU/mL	<i>Lactobacillus acidophilus</i>	1.0E+06 CFU/mL
<i>Acinetobacter lwoffii</i>	1.0E+06 CFU/mL	<i>Lactobacillus crispatus</i>	1.0E+06 CFU/mL
<i>Actinomyces israelii</i>	1.0E+06 CFU/mL	<i>Lactobacillus jensenii</i>	1.0E+06 CFU/mL
<i>Aerococcus viridans</i>	1.0E+06 CFU/mL	<i>Lactobacillus vaginalis</i>	1.0E+06 CFU/mL
<i>Aeromonas hydrophila</i>	1.0E+06 CFU/mL	<i>Leptotrichia buccalis</i>	1.0E+06 CFU/mL
<i>Alcaligenes faecalis subsp. faecalis</i>	1.0E+06 CFU/mL	<i>Leuconostoc mesenteroides subsp. mesenteroides</i>	1.0E+06 CFU/mL
<i>Atopobium vaginae</i>	1.0E+06 CFU/mL	<i>Leuconostoc paramesenteroides</i>	1.0E+06 CFU/mL
<i>Bacillus subtilis</i>	1.0E+06 CFU/mL	<i>Listeria monocytogenes</i>	1.0E+06 CFU/mL
<i>Bacteroides fragilis</i>	1.0E+06 CFU/mL	<i>Micrococcus luteus</i>	1.0E+06 CFU/mL
<i>Bacteroides ureolyticus</i>	1.0E+06 CFU/mL	<i>Mobiluncus curtisii subsp. curtisii</i>	1.0E+06 CFU/mL

<i>Bifidobacterium adolescentis</i>	1.0E+06 CFU/mL	<i>Moraxella osloensis</i>	1.0E+06 CFU/mL
<i>Branhamella catarrhalis</i>	1.0E+06 CFU/mL	<i>Moraxella catarrhalis</i>	1.0E+06 CFU/mL
<i>Brevibacterium linens</i>	1.0E+06 CFU/mL	<i>Moraxella lacunata</i>	1.0E+06 CFU/mL
<i>Campylobacter jejuni</i>	1.0E+06 CFU/mL	<i>Morganella morganii</i>	1.0E+06 CFU/mL
<i>Candida albicans</i>	1.0E+06 CFU/mL	<i>Mycobacterium smegmatis</i>	1.0E+06 CFU/mL
<i>Candida glabrata</i>	1.0E+06 CFU/mL	<i>Mycoplasma faucium</i>	1.0E+06 CFU/mL
<i>Candida parapsilosis</i>	1.0E+06 CFU/mL	<i>Mycoplasma fermentans</i>	1.0E+06 CFU/mL
<i>Candida tropicalis</i>	1.0E+06 CFU/mL	<i>Mycoplasma hominis</i>	1.0E+06 CFU/mL
<i>Chlamydia trachomatis</i>	1.0E+06 CFU/mL	<i>Mycoplasma orale</i>	1.0E+06 CFU/mL
<i>Chromobacterium violaceum</i>	1.0E+06 CFU/mL	<i>Mycoplasma penetrans</i>	1.0E+06 CFU/mL
<i>Citrobacter braakii</i>	1.0E+06 CFU/mL	<i>Mycoplasma pirum</i>	1.0E+06 CFU/mL
<i>Clostridium perfringens</i>	1.0E+06 CFU/mL	<i>Mycoplasma pneumoniae</i>	1.0E+06 CFU/mL
<i>Clostridioides difficile</i> serogroup B	1.0E+06 CFU/mL	<i>Mycoplasma primatum</i>	1.0E+06 CFU/mL
<i>Corynebacterium genitalium</i>	1.0E+06 CFU/mL	<i>Mycoplasma salivarium</i> DNA	1.0E+06 cp/mL
<i>Corynebacterium xerosis</i>	1.0E+06 CFU/mL	<i>Mycoplasma spermatophilum</i>	1.0E+06 ccu/mL
<i>Cryptococcus neoformans</i>	1.0E+06 CFU/mL	<i>Neisseria gonorrhoeae</i>	1.0E+06 CFU/mL
Cytomegalovirus	1.0E+05 IU/mL	<i>Pentatrichomonas hominis</i>	1.0E+06 CFU/mL
<i>Derxia gummosa</i>	1.0E+06 CFU/mL	<i>Peptostreptococcus anaerobius</i>	1.0E+06 CFU/mL
<i>Dientamoeba fragilis</i>	1.0E+06 CFU/mL	<i>Prevotella bivia</i>	1.0E+06 CFU/mL
<i>Eikenella corrodens</i>	1.0E+06 CFU/mL	<i>Propionibacterium acnes</i>	1.0E+06 CFU/mL
<i>Enterobacter aerogenes</i>	1.0E+06 CFU/mL	<i>Proteus mirabilis</i>	1.0E+06 CFU/mL
<i>Enterobacter cloacae</i>	1.0E+06 CFU/mL	<i>Providencia stuartii</i>	1.0E+06 CFU/mL
<i>Enterococcus avium</i>	1.0E+06 CFU/mL	<i>Pseudomonas aeruginosa</i>	1.0E+06 CFU/mL
<i>Enterococcus faecalis</i>	1.0E+06 CFU/mL	<i>Rahnella aquatilis</i>	1.0E+06 CFU/mL
<i>Enterococcus faecium</i>	1.0E+06 CFU/mL	<i>Rhizobium radiobacter</i>	1.0E+06 CFU/mL
<i>Erysipelothrix rhusiopathiae</i>	1.0E+06 CFU/mL	<i>Rhodospirillum rubrum</i>	1.0E+06 CFU/mL
<i>Escherichia coli</i>	1.0E+06 CFU/mL	<i>Saccharomyces cerevisiae</i>	1.0E+06 CFU/mL
<i>Flavobacterium meningosepticum</i>	1.0E+06 CFU/mL	<i>Salmonella minnesota</i>	1.0E+06 CFU/mL
<i>Fusobacterium nucleatum</i>	1.0E+06 CFU/mL	<i>Serratia marcescens</i>	1.0E+06 CFU/mL
<i>Gardnerella vaginalis</i>	1.0E+06 CFU/mL	<i>Staphylococcus aureus</i> MSSA NRS 164	1.0E+06 CFU/mL
<i>Gemella haemolysans</i>	1.0E+06 CFU/mL	<i>Staphylococcus epidermidis</i>	1.0E+06 CFU/mL
<i>Giardia intestinalis</i>	1.0E+06 CFU/mL	<i>Streptococcus agalactiae</i>	1.0E+06 CFU/mL
<i>Haemophilus ducreyi</i>	1.0E+06 CFU/mL	<i>Streptococcus pneumoniae</i>	1.0E+06 CFU/mL
Herpes Simplex Virus Type 1	1.0E+05 cp/mL	<i>Streptococcus pyogenes</i>	1.0E+06 CFU/mL
Herpes Simplex Virus Type 2	1.0E+05 cp/mL	<i>Trichomonas tenax</i>	1.0E+04 CFU/mL*
<i>Mycoplasma hominis</i>	1.0E+06 CFU/mL	<i>Ureaplasma urealyticum</i>	1.0E+06 ccu/mL
Human immunodeficiency virus	1.0E+05 cp/mL	<i>Veillonella parvula</i>	1.0E+06 CFU/mL
Human Papillomavirus type 16	1.0E+05 cells/mL	<i>Vibrio parahaemolyticus</i>	1.0E+06 CFU/mL
<i>Kingella denitrificans</i>	1.0E+06 CFU/mL	<i>Yersinia enterocolitica</i>	1.0E+06 CFU/mL

\*Level at which no interference with TV detection observed, tested also at 1.0E+06 CFU/mL which showed interference with TV, but not with MG



## Interference

The effect of over-the-counter or prescription feminine products that may be present in urogenital specimens (Table 24) were evaluated. Testing was done using pooled clinical and contrived specimens spiked with potential interferents at levels expected from normal patient usage and in absence and presence of TV and MG target (spiked at approximately 3 x LoD).

Of the over-the-counter (OTC) feminine hygiene and prescription products tested in urogenital specimens, Metronidazole Vaginal Gel by Sandoz, Replens™ and RepHresh™ produced false negative or invalid results. These products contain carbomer(s). Products containing carbomer(s) have been shown to generate false negative and invalid results. Table 24 is not intended to be a comprehensive list of carbomer containing products.

**Table 24** List of substances tested for interference in urogenital specimens

Product Name		
Clindamycin Phosphate Vaginal Cream	Monistat® Complete Care Itch Relief Cream	Yeast Gard Advanced
CVS tioconazole 1 (Equate tioconazole 1)	Gyne-Lotrimin 7	Glacial acetic acid
Equate Vagicare Anti-Itch Cream	Norforms Suppositories	Azo Standard (Urine only)
Estrace	Premarin	RepHresh™ Clean Balance*
K-Y™ UltraGel (Replaces KY Silk E)	Replens™ Long-Lasting Vaginal Moisturizer*	Arilin rapid vaginal suppositories**
Metronidazole Vaginal Gel by Sandoz*	Summer's Eve Feminine Deodorant Spray	Vagi Metro Cream**
Monistat 3 Vaginal Antifungal Combination Pack	Vaginal Contraceptive Foam	Nidazea Gel**

\* Metronidazole Vaginal Gel by Sandoz, Replens™ and RepHresh™ showed interference at levels that may potentially be present in clinical specimens.

\*\*Products containing metronidazole which did not show interference, in contrast to the Metronidazole Vaginal Gel by Sandoz.

Endogenous substances that may be present in urogenital specimens were tested for interference. Testing was done using pooled clinical and contrived specimens spiked with potential interferents at elevated levels and in absence and presence of TV and MG target (spiked at approximately 3 x LoD).

None of the substances interfered with the test performance by generating false-negative or false-positive results. Levels of endogenous substances tolerated by the assay for all specimen types are shown in Table 25.

**Table 25** Summary of endogenous substance concentrations that do not show interference

Interferent	Endocervical Swab	Meatal Swab	Cervical Specimens	Urine
Albumin (% w/v)	N/A	N/A	N/A	0.5%
Bilirubin (% w/v)	N/A	N/A	N/A	1.0%
Mucus*	present	present	present	present
Glucose (% w/v)	N/A	N/A	N/A	1.0 %
Peripheral Blood Mononuclear Cells	1.0E+06 cells/mL	N/A	1.0E+06 cells/mL	1.0E+06 cells/mL
pH (acidic and alkaline)	N/A	N/A	N/A	pH 4 and pH 9
Semen	22 mg/mL	20 mg/mL	4 mg/mL	13 mg/mL
Whole Blood (% v/v)	10%	N/A	10%	10%

\*One mucus swab per sample reflecting the maximum level that could be found in patient sample

## Competitive inhibition

To assess competitive inhibition between TV and MG, samples of each specimen type (swabs and meatal swabs in **cobas**® PCR Media, urine stabilized in **cobas**® PCR Media and cervical specimens in PreservCyt® Solution) were tested. Low and moderate concentrations of one target were mixed with very high concentrations of the opposite target. Low and moderate concentrations were defined as ~1 x LoD and ~3 x LoD, respectively, and high concentrations were defined as those generating a signal greater than in 95% of target positive clinical specimens.

Testing results indicated that when MG was present at a high concentration, TV was detected in all specimen types, at both low (~1 x LoD) and moderate (~3 x LoD) levels. Results also indicated that when TV was present at a high concentration, MG was detected in all specimen types both low (~1 x LoD) and moderate (~3 x LoD) levels.

## Whole system failure

The samples tested in the whole system failure study were pooled negative urine stabilized in **cobas**® PCR Media, as well as contrived matrices equivalent to vaginal and meatal swab specimens collected in **cobas**® PCR Media or cervical specimens collected in PreservCyt® Solution, co-spiked with TV and MG target to a concentration of approximately 3 x LoD of the respective target and matrix. The results of this study determined that all replicates were valid and positive for TV and MG, resulting in a whole system failure rate of 0%. The two-sided 95% exact confidence interval was 0% for the lower bound and 3.6% for the upper bound [0%: 3.6%].

## Cross contamination

Studies were performed to evaluate potential cross contamination on the **cobas**® 6800/8800 systems using **cobas**® TV/MG. Cross-contamination can cause false positive results. In this performance study the sample to sample cross-contamination rate of **cobas**® TV/MG has been determined to be 0.7% (4/576) for TV and 0.0% (0/480) for MG when alternating very high positive and negative samples were tested over multiple runs. Testing was done using samples prepared with **cobas**® PCR Media and with PreservCyt® Solution. High positive samples in the study were prepared to generate a Ct value that exceeds 95% or more of signal obtained from specimens of infected patients in the intended use population. The likelihood of encountering such specimens in the routine use of **cobas**® TV/MG is proportional to TV prevalence in the testing population. Therefore the sample to sample cross-contamination rate for TV in routine use of **cobas**® TV/MG will likely be less than  $0.7\% \times 5\% \times \text{TV prevalence in the testing population}$ . With the prevalence of 8.1%<sup>1</sup> in female patients, the cross-contamination rate would be  $0.7\% \times 5\% \times 8.1\% = 0.003\%$ .

## Clinical performance evaluation

The performance of cobas® TV/MG for *T. vaginalis* was compared to a composite reference method comprised of the Hologic Aptima® TV Assay, and two laboratory developed PCR tests each targeting genome regions of TV that are different from cobas® TV/MG. Using the “two-out-of-three” rule, the infected status was defined for the following specimen types for each subject:

- Endocervical swabs in cobas® PCR Media
- Vaginal swabs (clinician-collected) in cobas® PCR Media
- Vaginal swabs (self-collected) in cobas® PCR Media
- Female urine stabilized in cobas® PCR Media
- Cervical specimens collected in PreservCyt® Solution

A total of 412 subjects were recruited from multiple sites in Germany, Ukraine, and the US. Results are shown in Table 26.

**Table 26** Sensitivity and specificity of TV of cobas® TV/MG in female specimens

Specimen Type	<i>Trichomonas vaginalis</i>		
		Result (%)	95% CI
Endocervical Swab	Sensitivity	100% (22/22)	84.6%-100%
	Specificity	99.2% (387/390)	97.8%-99.8%
Vaginal Swab - Combined	Sensitivity	100% (25/25)	86.3%-100%
	Specificity	99.7% (386/387)	98.6%-100%
CC - Vaginal Swab	Sensitivity	100% (14/14)	76.8%-100%
	Specificity	100% (208/208)	98.2%-100%
SC- Vaginal Swab	Sensitivity	100% (11/11)	71.5%-100%
	Specificity	99.4% (178/179)	96.9%-100%
Female Urine	Sensitivity	100% (25/25)	86.3%-100%
	Specificity	99.7% (386/387)	98.6%-100%
PreservCyt®	Sensitivity	100% (23/23)	85.2%-100%
	Specificity	99.5% (387/389)	98.2%-99.9%

CC = Clinician-Collected; SC = Self-Collected.

Note: There is no statistically significant difference between results from self-collected and clinician-collected vaginal swabs.

Additionally, cobas® TV/MG results were compared directly to Hologic Aptima® TV Assay results (Table 27).

**Table 27** Correlation between TV of cobas® TV/MG and Hologic Aptima® TV Assay

Specimen Type	<i>Trichomonas vaginalis</i>			
	Con +	Con -	cobas+/Aptima -	cobas -/Aptima +
Endocervical Swab	20	378	5	9
Vaginal Swab	24	383	2	3
Female Urine	26	386	0	0
PreservCyt®	21	386	4	1
All Specimens Total	91	1533	11	13

Con = Concordant; + = Positive; - = Negative

Testing of the 24 specimens where results were discrepant between cobas® TV/MG and the Hologic Aptima® TV Assay by an alternative PCR test generated 18 results that were in agreement with cobas® TV/MG (including all 13 cobas-/Aptima+

and 5 out of 11 cobas+/Aptima-) and 6 results in agreement with the Hologic Aptima® TV Assay (all cobas+/Aptima-).

The performance of cobas® TV/MG for *T. vaginalis* in male urine stabilized in cobas® PCR Media was compared to a composite reference method comprised of the Xpert TV Assay, and two laboratory developed PCR tests each targeting genome regions of TV that are different from cobas® TV/MG. Using the “two-out-of-three” rule, the infected status was defined for each subject.

A total of 424 subjects were recruited from multiple sites in Germany, Ukraine and the US. Results are shown in Table 28.

**Table 28** Sensitivity and specificity of TV of cobas® TV/MG in male urine

Specimen Type	<i>Trichomonas vaginalis</i>		
		Result (%)	95% CI
Male Urine	Sensitivity	100% (6/6)	54.1%-100%
	Specificity	99.3% (415/418)	97.9%-99.9%

Additionally, cobas® TV/MG results were compared directly to Xpert TV Test results (Table 29).

**Table 29** Correlation between TV of cobas® TV/MG and Xpert TV Test

Specimen Type	<i>Trichomonas vaginalis</i>			
	Con +	Con -	cobas+/Xpert -	cobas -/Xpert +
Male Urine	5	415	4	0

Con = Concordant; + = Positive; - = Negative

The performance of cobas® TV/MG in meatal swab specimen (clinician and self-collected) was compared to performance in urine specimen for each subject.

A total of 424 subjects were recruited from multiple sites in Germany, Ukraine and the US.

Results are shown in Table 30 and Table 31. Overall Percent Agreement was 96.7%.

**Table 30** Results summary for correlation for TV between meatal swab and urine specimen using cobas® TV/MG

Specimen Type	<i>Trichomonas vaginalis</i>			
	Con +	Con -	MS+/UR -	MS -/UR +
Meatal Swab - Combined	8	402	13	1
CC - Meatal Swab	4	206	5	0
SC - Meatal Swab	4	196	8	1

Con = Concordant; MS = Meatal Swab; UR = Urine; + = Positive; - = Negative; CC = Clinician-Collected; SC = Self-Collected

**Table 31** Agreement calculations for correlation for TV between meatal swab and urine specimen using cobas® TV/MG

Specimen Type	<i>Trichomonas vaginalis</i>		
		Result (%)	95% CI
Meatal Swab - Combined	PPA	88.9% (8/9)	51.8%-99.7%
	NPA	96.9% (402/415)	94.7%-98.3%
	OPA	96.7% (410/424)	94.5%-98.2%
CC - Meatal Swab	PPA	100% (4/4)	39.8%-100%
	NPA	97.6% (206/211)	94.6%-99.2%
	OPA	97.7% (210/215)	94.7%-99.2%
SC - Meatal Swab	PPA	80.0% (4/5)	28.4%-99.5%
	NPA	96.1% (196/204)	92.4%-98.3%
	OPA	95.7% (200/209)	92.0%-98.0%

PPA = Positive Percent Agreement; NPA = Negative Percent Agreement; OPA = Overall Percent Agreement;

CC = Clinician-Collected; SC = Self-Collected

Note: There is no statistically significant difference between results from self-collected and clinician collected meatal swabs.

The performance of cobas® TV/MG for *M. genitalium* was compared to a composite reference method comprised of the Hologic Aptima® MG Assay, and two laboratory developed PCR tests each targeting genome regions of MG that are different from cobas® TV/MG. Using the “two-out-of-three” rule, the infected status was defined for the following specimen types for each subject:

- Endocervical swabs in cobas® PCR Media
- Vaginal swabs (clinician-collected) in cobas® PCR Media
- Vaginal swabs (self-collected) in cobas® PCR Media
- Male and female urine stabilized in cobas® PCR Media
- Meatal swabs (clinician-collected) in cobas® PCR Media
- Meatal swabs (self-collected) in cobas® PCR Media
- Cervical specimens collected in PreservCyt® Solution

A total of 836 subjects were recruited from multiple sites in Germany, Ukraine, and the US. Results are shown in Table 32.

**Table 32** Sensitivity and specificity for MG of cobas® TV/MG

Specimen Type	<i>Mycoplasma genitalium</i>		
		Result (%)	95% CI
Endocervical Swab	Sensitivity	100% (16/16)	79.4%-100%
	Specificity	99.0% (392/396)	97.4%-99.7%
Vaginal Swab - Combined	Sensitivity	96.2% (25/26)	80.4%-99.9%
	Specificity	99.0% (382/386)	97.4%-99.7%
CC - Vaginal Swab	Sensitivity	100% (15/15)	78.2%-100%
	Specificity	98.6% (204/207)	95.8%-99.7%
SC - Vaginal Swab	Sensitivity	90.9% (10/11)	58.7%-99.8%
	Specificity	99.4% (178/179)	96.9%-100%
Female Urine	Sensitivity	100% (26/26)	86.8%-100%
	Specificity	97.7% (377/386)	95.6%-98.9%
Male Urine	Sensitivity	100% (39/39)	91.0%-100%
	Specificity	98.7% (380/385)	97.0%-99.6%
Meatal Swab - Combined	Sensitivity	100% (21/21)	83.9%-100%
	Specificity	98.3% (396/403)	96.5%-99.3%
CC - Meatal Swab	Sensitivity	100% (8/8)	63.1%-100%
	Specificity	98.1% (203/207)	95.1%-99.5%
SC - Meatal Swab	Sensitivity	100% (13/13)	75.3%-100%
	Specificity	98.5% (193/196)	95.6%-99.7%
PreservCyt®	Sensitivity	91.3% (21/23)	72.0%-98.9%
	Specificity	99.0% (385/389)	97.4%-99.7%

CC = Clinician-Collected; SC = Self-Collected.

Note: There was no statistically significant difference between results from self-collected and clinician collected vaginal and meatal swabs.

Additionally, cobas® TV/MG results were compared directly to Hologic Aptima® MG Assay results (Table 33).

**Table 33** Correlation between MG of cobas® TV/MG and Hologic Aptima® MG Assay

Specimen Type	<i>Mycoplasma genitalium</i>			
	Con +	Con -	cobas+/Aptima -	cobas -/Aptima +
Endocervical Swab	20	383	0	9
Vaginal Swab	27	374	2	9
Female Urine	30	373	5	4
Male Urine	41	375	3	5
Meatal Swab	26	384	2	12
PreservCyt®	25	381	0	6
All Specimens Total	169	2270	12	45

Con = Concordant; + = Positive; - = Negative

Testing of the 57 specimens where results were discrepant between cobas® TV/MG and the Hologic Aptima® MG Assay by an alternative PCR test generated 50 results that were in agreement with cobas® TV/MG (including all 45 cobas-/Aptima+ and 5 out of 12 cobas+/Aptima-) and 7 results in agreement with the Hologic Aptima® MG Assay (all cobas+/Aptima-).

## Additional information

### Key assay features





















































<b>Sample types</b>	<ul style="list-style-type: none"><li>• Endocervical swab collected in <b>cobas</b>® PCR Media</li><li>• Vaginal swab collected in <b>cobas</b>® PCR Media</li><li>• Self-collected Vaginal swab collected in <b>cobas</b>® PCR Media</li><li>• Meatal swab collected in <b>cobas</b>® PCR Media</li><li>• Self-collected Meatal swab collected in <b>cobas</b>® PCR Media</li><li>• Male and female urine stabilized in <b>cobas</b>® PCR Media</li><li>• Cervical specimens collected in PreservCyt® Solution</li></ul>
<b>Amount of sample required/processed</b>	<ul style="list-style-type: none"><li>• ≥ 1000 µL required in sample tube for swab samples, instrument processes 400 µL</li><li>• ≥ 1000 µL required in sample tube for PreservCyt® samples, instrument processes 400 µL</li><li>• ≥ 1200 µL required in sample tube for meatal swab samples, instrument processes 850 µL</li><li>• ≥ 1200 µL required in sample tube for urine samples, instrument processes 850 µL</li><li>• On <b>cobas</b>® 5800 system, ≥ 3000 µL required in sample tube for PreservCyt® samples in primary tubes, instrument processes 400 µL</li></ul>
<b>Test duration</b>	<ul style="list-style-type: none"><li>• &lt; 3.5 hours to first result</li></ul>



## Symbols

The following symbols are used in labeling for Roche PCR diagnostic products.

**Table 34** Symbols used in labeling for Roche PCR diagnostics products

 Age/DOB	 Device not for near-patient testing	 QS IU/PCR	QS IU per PCR reaction, use the QS International Units (IU) per PCR reaction in calculation of the results.
 Ancillary Software	 Device not for self-testing		
 Assigned Range [copies/mL]	 Distributor (Note: The applicable country/region may be designated beneath the symbol)	 SN	Serial number
 Assigned Range [IU/mL]	 Do not re-use	 Site	Site
 EC REP	 Female	 Procedure Standard	Standard Procedure
 Barcode Data Sheet	 For IVD performance evaluation only	 STERILE EO	Sterilized using ethylene oxide
 LOT	 GTIN	 Store in dark	
 Biological risks	 Importer	 Temperature limit	
 REF	 IVD	 TDF	Test Definition File
 CE marking of conformity; this device is in conformity with the applicable requirements for CE marking of an in vitro diagnostic medical device	 LLR	 This way up	
	 Male	 Procedure UltraSensitive	Ultrasensitive Procedure
 Collect Date	 Manufacturer	 UDI	Unique Device Identifier
 Consult instructions for use	 CONTROL -	 ULR	Upper Limit of Assigned Range
 Contains sufficient for <n> tests	 Non-sterile	 Urine Fill Line	Urine Fill Line
 CONTENT	 Patient Name	 Rx only	For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.
 CONTROL	 Patient number	 Use-by date	
 Date of manufacture	 Peel here		
 Device for near-patient testing	 CONTROL +		
 Device for self-testing	 QS copies / PCR		QS copies per PCR reaction, use the QS copies per PCR reaction in calculation of the results.

## Technical support

For technical support (assistance) please reach out to your local affiliate:

[https://www.roche.com/about/business/roche\\_worldwide.htm](https://www.roche.com/about/business/roche_worldwide.htm)

## Manufacturer and importer

**Table 35** Manufacturer and importer



Roche Molecular Systems, Inc.  
1080 US Highway 202 South  
Branchburg, NJ 08876, USA  
[www.roche.com](http://www.roche.com)



Made in USA

Roche Diagnostics GmbH  
Sandhofer Strasse 116  
68305 Mannheim, Germany

## Trademarks and patents

See <https://diagnostics.roche.com/us/en/about-us/patents>

## Copyright

©2024 Roche Molecular Systems, Inc.



Roche Diagnostics GmbH  
Sandhofer Str. 116  
68305 Mannheim  
Germany



## References

1. Kissinger P. *Trichomonas vaginalis*: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis. 2015;15:307. doi:10.1186/s12879-015-1055-0.
2. Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S, Markowitz L. The prevalence of *Trichomonas vaginalis* infection among reproductive-age women in the United States, 2001–2004. Clin Infect Dis. 2007;45(10): 1319-26.
3. Andrea SB, Chapin KC. Comparison of Aptima *Trichomonas vaginalis* transcription-mediated amplification assay and BD affirm VPIII for detection of *T. vaginalis* in symptomatic women: performance parameters and epidemiological implications. J Clin Microbiol. 2011;49(3):866-9. doi:10.1128/JCM.02367-10.
4. Update on Laboratory Diagnosis and Epidemiology of *Trichomonas vaginalis*: You Can Teach an “Old” Dog “New” Trichs. Munson, Erik et al. Clinical Microbiology Newsletter, Volume 38, Issue 20, 159 - 168.
5. Schwebke JR, Burgess D. Trichomoniasis. Clin Microbiol Rev. 2004; 17(4):794-803, table of contents.
6. Patil MJ, Nagamoti JM, Metgud SC. Diagnosis of *Trichomonas Vaginalis* from vaginal specimens by wet mount microscopy, in pouch tv culture system, and PCR. J Global Infect Dis. 2012;4(1):22-5. doi:10.4103/0974-777X.93756.
7. Nye MB, Schwebke JR, Body BA. Comparison of APTIMA *Trichomonas vaginalis* transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol. 2009;200(2):188.e1-7. doi: 10.1016/j.ajog.2008.10.005.
8. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64(RR-03):1-137.
9. Tully JG, Taylor-Robinson D, Cole RM, Rose DL. A newly discovered mycoplasma in the human urogenital tract. Lancet. 1981; Jun; 1(8233):1288-91.
10. Jensen JS. *Mycoplasma genitalium* infections. Diagnosis, clinical aspects, and pathogenesis. Dan Med Bull. 2006; 53(1):1–27.
11. Daley GM, Russell DB, Tabrizi SN, McBride J. *Mycoplasma genitalium*: a review. Int J STD AIDS. 2014; 25(7):475-87. doi: 10.1177/0956462413515196.
12. Getman D, Jiang A, O'Donnell M, Cohen S. *Mycoplasma genitalium* Prevalence, Coinfection, and Macrolide Antibiotic Resistance Frequency in a Multicenter Clinical Study Cohort in the United States. J Clin Microbiol. 2016; 54(9):2278-83. doi:10.1128/JCM.01053-16.
13. Lillis RA, Nsuami MJ, Myers L, Martin DH. Utility of urine, vaginal, cervical, and rectal specimens for detection of *Mycoplasma genitalium* in women. J Clin Microbiol. 2011; 49(5):1990-2. doi: 10.1128/JCM.00129-11.
14. Mezzini TM, Waddell RG, Douglas RJ, Sadlon TA. *Mycoplasma genitalium*: prevalence in men presenting with urethritis to a South Australian public sexual health clinic. Intern Med J. 2013; 43(5):494-500. doi: 10.1111/imj.12103.
15. Longo MC, Berninger, MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990; 93:125-8.
16. Higuchi R, Dollinger, G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Bio/Technology 1992; 10:413-7.
17. Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR. Genome Research. 1996; 6:986-94.

18. Center for Disease Control and Prevention. Biosafety in microbiological and biomedical laboratories, 5th ed. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institutes of Health HHS Publication No. (CDC) 21-1112, revised December 2009.
19. Clinical and Laboratory Standards Institute (CLSI). Protection of laboratory workers from occupationally acquired infections. Approved Guideline-Fourth Edition. CLSI Document M29-A4:Wayne, PA;CLSI, 2014.
20. International Air Transport Association. Dangerous Goods Regulations, 57th Edition. 2016.

## Document revision

Document Revision Information	
Doc Rev. 3.0 12/2024	<p>Added software version 2.0 information for <b>cobas</b>® 6800/8800 systems.</p> <p>Updated display of example results on <b>cobas</b>® 6800/8800 systems with software version 1.4.</p> <p>P/Ns of consumables removed, detailed information on <b>consumables</b> are referenced in the <b>cobas</b>® 5800 and <b>cobas</b>® 6800/8800 systems User Assistance.</p> <p>Removed Rx Only from front page.</p> <p>Updated overall CV (%) ranges for TV in the <b>Precision</b> section.</p> <p>Updated the harmonized symbol page.</p> <p>Please contact your local Roche Representative if you have any questions.</p>

The summary of safety and performance report can be found using the following link: <https://ec.europa.eu/tools/eudamed>